News

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • CAMBRIDGE, Mass, June 07, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on June 5, 2024, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants covering an aggregate of 6,188 shares of its common stock to one new employee, consisting of stock options to purchase 4,125 shares of common stock and restricted stock units (“RSUs”) covering 2,063 shares of its common stock.
    06/07/2024

Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023

  • Transaction ensures Nestlé Health Science will continue to commercialize the product BRIDGEWATER, N.J. , June 6, 2024 /PRNewswire/ -- Seres Therapeutics, Inc. (Nasdaq: MCRB), announced today that it has agreed to a non-binding memorandum of understanding with Nestlé Health Science in which Nestlé Health Science will acquire certain tangible and intangible assets associated with VOWST (fecal microbiota spores, live-brpk) capsules.
    06/06/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Seres Therapeutics, Inc. (MCRB) can hold. Click on Rating Page for detail.

The price of Seres Therapeutics, Inc. (MCRB) is 0.6845 and it was updated on 2024-06-17 09:00:53.

Currently Seres Therapeutics, Inc. (MCRB) is in undervalued.

News
    
News

Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science

  • Seres anticipates capital infusions, including an upfront payment, enabling the Company to fully retire its debt and extend its cash runway into Q4 2025, pending deal closure and subject to performance under a transition services agreement
    Thu, Jun. 06, 2024

Seres Therapeutics, Inc. (MCRB) Q1 2024 Earnings Call Transcript

  • Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q1 2024 Results Conference Call May 8, 2024 8:30 AM ET Company Participants Carlo Tanzi - IR Eric Shaff - CEO Terri Young - Chief Commercial and Strategy Officer Lisa von Moltke - Chief Medical Officer Marella Thorell - CFO Matthew Henn - EVP, Chief Scientific Officer Conference Call Participants Ted Tenthoff - Piper Sandler John Newman - Canaccord Genuity Tess Romero - JPMorgan Jeff Jones - Oppenheimer Keay Nakae - Chardan Operator Thank you for standing by. My name is Alex, and I will be your conference operator today.
    Sat, May. 11, 2024

Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2024 financial results and provided business updates. "With a broad indication and compelling clinical profile to prevent the recurrence of Clostridioides difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI), VOWST enables healthcare providers to fundamentally transform how they treat this life-threatening d.
    Wed, May. 08, 2024

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on May 1, 2024, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants covering an aggregate of 9,367 shares of its common stock to two new employees, consisting of stock options to purchase 6,244 shares of common stock and restricted stock units (“RSUs”) covering 3,123 shares of its co.
    Mon, May. 06, 2024

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 8, 2024 at 8:30 a.m. ET to discuss first quarter 2024 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 5686561. To join the live webcast, please visit th.
    Mon, May. 06, 2024
SEC Filings
SEC Filings

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 05/17/2024

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 04/08/2024

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 03/27/2024

Seres Therapeutics, Inc. (MCRB) - 3

  • SEC Filings
  • 03/27/2024

Seres Therapeutics, Inc. (MCRB) - S-8

  • SEC Filings
  • 03/05/2024

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 02/16/2024

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 10/31/2023

Seres Therapeutics, Inc. (MCRB) - S-3

  • SEC Filings
  • 08/08/2023

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 06/23/2023

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 05/01/2023

Seres Therapeutics, Inc. (MCRB) - S-8

  • SEC Filings
  • 03/07/2023

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 02/07/2023

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 01/05/2023

Seres Therapeutics, Inc. (MCRB) - 3

  • SEC Filings
  • 01/05/2023

Seres Therapeutics, Inc. (MCRB) - S-8

  • SEC Filings
  • 12/30/2022

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 10/31/2022

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 07/07/2022

Seres Therapeutics, Inc. (MCRB) - 3

  • SEC Filings
  • 07/07/2022

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 07/06/2022

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 06/24/2022

Seres Therapeutics, Inc. (MCRB) - S-8

  • SEC Filings
  • 03/01/2022

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 02/08/2022

Seres Therapeutics, Inc. (MCRB) - 3

  • SEC Filings
  • 02/08/2022

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 06/21/2021

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 06/01/2021

Seres Therapeutics, Inc. (MCRB) - 3

  • SEC Filings
  • 06/01/2021

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 05/19/2021

Seres Therapeutics, Inc. (MCRB) - S-8

  • SEC Filings
  • 03/02/2021

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 02/08/2021

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 12/03/2020

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 11/25/2020

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 10/21/2020

Seres Therapeutics, Inc. (MCRB) - 3

  • SEC Filings
  • 10/21/2020

Seres Therapeutics, Inc. (MCRB) - FWP

  • SEC Filings
  • 08/17/2020

Seres Therapeutics, Inc. (MCRB) - FWP

  • SEC Filings
  • 08/13/2020

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 07/01/2020

Seres Therapeutics, Inc. (MCRB) - 3

  • SEC Filings
  • 07/01/2020

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 06/22/2020

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 04/24/2020

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 04/07/2020

Seres Therapeutics, Inc. (MCRB) - 3

  • SEC Filings
  • 04/07/2020

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 03/23/2020

Seres Therapeutics, Inc. (MCRB) - 3

  • SEC Filings
  • 03/23/2020

Seres Therapeutics, Inc. (MCRB) - S-3

  • SEC Filings
  • 03/09/2020

Seres Therapeutics, Inc. (MCRB) - S-8

  • SEC Filings
  • 03/02/2020

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 01/31/2020

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 01/28/2020

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 11/25/2019

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 08/06/2019

Seres Therapeutics, Inc. (MCRB) - 3

  • SEC Filings
  • 08/06/2019

Seres Therapeutics, Inc. (MCRB) - 3

  • SEC Filings
  • 06/28/2019

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 06/20/2019

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 06/14/2019

Seres Therapeutics, Inc. (MCRB) - 3

  • SEC Filings
  • 04/24/2019

Seres Therapeutics, Inc. (MCRB) - S-8

  • SEC Filings
  • 03/06/2019

Seres Therapeutics, Inc. (MCRB) - 3/A

  • SEC Filings
  • 02/15/2019

Seres Therapeutics, Inc. (MCRB) - 3

  • SEC Filings
  • 02/11/2019

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 01/29/2019

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 12/19/2018

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 11/19/2018

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 10/24/2018

Seres Therapeutics, Inc. (MCRB) - 3

  • SEC Filings
  • 10/24/2018

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 10/16/2018

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 09/19/2018

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 09/11/2018

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 09/06/2018

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 09/04/2018

Seres Therapeutics, Inc. (MCRB) - 3

  • SEC Filings
  • 09/04/2018

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 07/18/2018

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 07/12/2018

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 07/10/2018

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 06/29/2018

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 06/27/2018

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 06/22/2018

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 06/19/2018

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 06/18/2018

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 05/10/2018

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 04/26/2018

Seres Therapeutics, Inc. (MCRB) - S-8

  • SEC Filings
  • 03/08/2018

Seres Therapeutics, Inc. (MCRB) - 4/A

  • SEC Filings
  • 01/30/2018

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 01/30/2018

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 01/25/2018

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 12/20/2017

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 07/20/2017

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 07/10/2017

Seres Therapeutics, Inc. (MCRB) - 3

  • SEC Filings
  • 07/10/2017

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 06/21/2017

Seres Therapeutics, Inc. (MCRB) - S-3

  • SEC Filings
  • 03/16/2017

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 01/27/2017

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 09/20/2016

Seres Therapeutics, Inc. (MCRB) - 4/A

  • SEC Filings
  • 08/31/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 08/30/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 07/29/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 07/28/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 07/26/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 07/07/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 07/05/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 06/30/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 06/29/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 06/17/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 06/06/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 06/02/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 05/27/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 05/25/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 05/19/2016

Seres Therapeutics, Inc. (MCRB) - 3

  • SEC Filings
  • 05/17/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 05/09/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 05/06/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 05/04/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 04/27/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 04/11/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 04/06/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 04/05/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 04/04/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 03/29/2016

Seres Therapeutics, Inc. (MCRB) - S-8

  • SEC Filings
  • 03/14/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 02/03/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 01/06/2016

Seres Therapeutics, Inc. (MCRB) - 3

  • SEC Filings
  • 01/06/2016

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 11/10/2015

Seres Therapeutics, Inc. (MCRB) - 3

  • SEC Filings
  • 11/10/2015

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 07/01/2015

Seres Therapeutics, Inc. (MCRB) - 4

  • SEC Filings
  • 06/29/2015

Seres Therapeutics, Inc. (MCRB) - S-8

  • SEC Filings
  • 06/26/2015

Seres Therapeutics, Inc. (MCRB) - 3

  • SEC Filings
  • 06/25/2015

Seres Therapeutics, Inc. (MCRB) - S-1

  • SEC Filings
  • 05/27/2015

Seres Therapeutics, Inc. (MCRB) - D

  • SEC Filings
  • 01/05/2015

Seres Therapeutics, Inc. (MCRB) - DRS

  • SEC Filings
  • 12/11/2014

Seres Therapeutics, Inc. (MCRB) - D

  • SEC Filings
  • 12/02/2014

Seres Therapeutics, Inc. (MCRB) - D

  • SEC Filings
  • 06/09/2014
Press Releases
StockPrice Release
More Headlines
News

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled Cohort 2 of its Phase 1b trial of SER-155 in patients who received Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT). SER-155 is an orally administered, consortium of bacteria, cultivated from cell banks and designed to reduce the incidence and severity of enteric-derived infections and resulting.
  • 04/09/2024

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on March 25, 2024, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants covering an aggregate of 700,000 shares of its common stock to Marella Thorell, the Company's new Executive Vice President and Chief Financial Officer, consisting entirely of stock options. These stock options are.
  • 03/28/2024

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on March 13, 2024, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants covering an aggregate of 6,188 shares of its common stock to one new employee, consisting of stock options to purchase 4,125 shares of common stock and restricted stock units (“RSUs”) covering 2,063 shares of its.
  • 03/19/2024

Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript

  • Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q4 2023 Earnings Call Transcript March 5, 2024 8:30 AM ET Company Participants Rob Windsor - IR Eric Shaff - CEO Terri Young - CCO & CSO Lisa von Moltke - CMO David Arkowitz - CFO Dave Ege - CTO Matthew Henn - Chief Scientific Officer Conference Call Participants Jeff Jones - Oppenheimer John Newman - Canaccord Tess Romero - JPMorgan Peyton Bohnsack - TD Cowen Chris Shibutani - Goldman Sachs Keay Nakae - Chardan Operator Ladies and gentlemen, good morning. My name is Abby, and will be your conference operator today.
  • 03/05/2024

Gold Price Alert: Gold Spot Prices Just Hit a Record High Today

  • Investors in gold are excited on Tuesday as the spot price of the precious metal hit a recent high of $2,113.28 per ounce during a rally yesterday. The increasing price of gold is catching up to its current record high of $2,135.40 that was achieved in December 2023.
  • 03/05/2024

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial results and provided business updates. “2023 was an historic year for Seres as we launched our first-in-class oral microbiome therapeutic, VOWST, for recurrent CDI into commercialization with our collaborators at Nestlé Health Science,” said Eric Shaff, President and Chief Executive Officer of Seres. “We are proud of th.
  • 03/05/2024

Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 5, 2024 at 8:30 a.m. ET to discuss fourth quarter and full year 2023 results and provide a general business update. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4030622. To join the live webcast,.
  • 02/28/2024

Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 9:10 a.m. ET. An audio webcast of the panel discussion will be available under the “Investors and News” section of Seres' website. A replay of the presentation will bec.
  • 02/27/2024

Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Marella Thorell will join as Executive Vice President and Chief Financial Officer (CFO), as of March 25th, following David Arkowitz's retirement. Mr. Arkowitz has served as CFO since June 2021 and will be available to assist in the transition. Ms. Thorell is a seasoned enterprise leader with deep life sciences and biotechnology industry experience in both p.
  • 02/26/2024

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on January 10, 2024, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants covering an aggregate of 67,500 shares of its common stock to one new employee, consisting of stock options to purchase 45,000 shares of common stock and restricted stock units (“RSUs”) covering 22,500 shares of.
  • 01/17/2024

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced preliminary key VOWST (fecal microbiota spores, live-brpk) launch metrics and receipt of US FDA Fast Track Designation for SER-155 ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10th. VOWST, the first FDA approved orally administered microbiome therapeutic, received FDA approval in April of 2023 and is indica.
  • 01/09/2024

Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024, at 12:45 p.m. ET / 9:45 am PT. An audio webcast of the presentation will be available under the “Investors and News” section of Seres' website. A replay of the presentation will become available approximately one hour after.
  • 01/04/2024

Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that preliminary clinical data from a currently enrolling Phase 1b study of SER-155 study in adult patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) will be presented at the 65th American Society of Hematology (ASH) Annual Meeting held from December 9-12, 2023, in San Diego, California, USA. SER-155 is an oral, cultivated live bacteria.
  • 12/07/2023

Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ET

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 3:30 p.m. ET. An audio webcast of the presentation will be available under the “Investors and News” section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archi.
  • 11/28/2023

Seres Therapeutics, Inc. (MCRB) Q3 2023 Earnings Call Transcript

  • Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q3 2023 Results Conference Call November 2, 2023 8:00 AM ET Company Participants Kevin Mannix - Head, IR Eric Shaff - CEO Dr. Terri Young - Chief Commercial Officer David Arkowitz - CFO Conference Call Participants Joseph Thome - TD Cowen Edward Tenthoff - Piper Sandler Tessa Romero - JPMorgan Jeff Jones - Oppenheimer Keay Nakae - Chardan Stephen Sloan - Goldman Sachs Operator Welcome to the Seres Therapeutics Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded.
  • 11/04/2023

Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported financial results for the third quarter ended September 30, 2023, including VOWST net sales of $7.6 million. Third quarter VOWST commercial results show strong continued progress, driven by a significant increase in new patient starts and exceeding the Company's forecasted expectations across multiple dimensions. VOWST is indicated to prevent the recurrence of Cl.
  • 11/02/2023

Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. EST

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will release third quarter 2023 financial results on Thursday, November 2, 2023. Management will host a conference call with investors to discuss the results and corporate updates at 8:00 a.m. ET. The conference call may be accessed by calling 1-866-777-2509 (international callers dial 1-412-317-5413). Participants may pre-register for the conference cal.
  • 10/30/2023

Seres Therapeutics: Approved Drug And Nestle Partnership Make It A Buy

  • Seres Therapeutics trades near its 52-week low and presents an asymmetric risk-reward profile. The company's lead asset, SER-109, has successfully concluded its Phase III clinical trial for recurrent Clostridioides difficile infection. Seres Therapeutics' partnership with Nestle provides financial backing and distribution support, highlighting the potential of its drug VOWST.
  • 09/01/2023

Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates

  • Seres Therapeutics (MCRB) came out with quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.55 per share. This compares to loss of $0.70 per share a year ago.
  • 08/08/2023

Best Penny Stocks To Buy? 5 With Big News This Week

  • Are you searching for some of the best penny stocks to buy now? I'm sure that if you're reading this article, that's something at the top of your mind.
  • 06/07/2023

Seres Therapeutics to Present at Jefferies Healthcare Conference

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will provide a corporate presentation at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:00 a.m. ET in New York City. An audio webcast of the presentation will be available under the “Investors and News” section of Seres' website. A replay of the presentation will b.
  • 06/02/2023

Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates

  • Seres Therapeutics (MCRB) came out with a quarterly loss of $0.57 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.61 per share a year ago.
  • 05/09/2023

Seres Gets FDA Approval And The Share Price Goes Down!

  • Biotech investing is a wild ride but share prices falling after FDA approval, as has just happened to Seres Therapeutics VOWST product, is pretty weird. On April 26, Seres achieved FDA approval for VOWST (formerly known as SER-109). This is the first FDA approval for an oral microbiomic product, a big deal for the microbiome.
  • 05/03/2023

Wall Street Thinks These 2 Nasdaq Stocks Could Go Parabolic Soon

  • Growth stocks fell across the board in 2022. This broad pullback may have created some tremendous buying opportunities.
  • 04/20/2023

Strength Seen in Seres Therapeutics (MCRB): Can Its 5.8% Jump Turn into More Strength?

  • Seres Therapeutics (MCRB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
  • 04/14/2023

Seres Therapeutics (MCRB) Moves 10.9% Higher: Will This Strength Last?

  • Seres Therapeutics (MCRB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
  • 03/22/2023

Seres Therapeutics, Inc. (MCRB) Q4 2022 Earnings Call Transcript

  • Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Carlo Tanzi - IR Officer Eric Shaff - President, CEO & Director Teresa Young - EVP and Chief Commercial & Strategy Officer Lisa von Moltke - EVP & Chief Medical Officer David Arkowitz - EVP, CFO & Head, Business Development David Ege - EVP & CTO Matthew Henn - EVP & Chief Scientific Officer Conference Call Participants Mark Breidenbach - Oppenheimer John Newman - Canaccord Genuity Edward Tenthoff - Piper Sandler & Co. Stephen Sloan - Goldman Sachs Group John Bohnsack - TD Cowen Operator Thank you for holding, and welcome everyone, to the Seres Therapeutics Fourth Quarter 2022 Conference Call. [Operator Instructions].
  • 03/07/2023

Seres Therapeutics (MCRB) Reports Q4 Loss, Misses Revenue Estimates

  • Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -31.71% and 89.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
  • 03/07/2023

Seres Therapeutics: FDA Approval Straight Ahead

  • Today, we take a look at microbiome therapeutic developer Seres Therapeutics, Inc. Seres Therapeutics appears headed to its first FDA approval and has a strategic partnership with Nestlé S.A. around this endeavor.
  • 02/06/2023

The Clock Is Ticking For Seres Therapeutics: I'm Not Afraid

  • April 26 is FDA decision day for SER-109, the Seres microbiome treatment for recurrent C. difficile infection. Finch Therapeutics gives up on Phase 3 trial for C. difficile recurrence; lays off 95% of staff.
  • 02/05/2023

Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial Strategy

  • CAMBRIDGE, Mass.--( BUSINESS WIRE )--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will host an investor webcast to discuss the planned commercialization approach and market opportunity for therapeutic candidate SER-109 in recurrent C. difficile infection (rCDI) on Thursday, December 8, 2022, at 8:30 a.m. ET and is expected to be approximately one hour in duration.
  • 11/22/2022

Seres Gets Closer To Good Times

  • After accepting the BLA for SER-109, the FDA has not announced the need for an expert advisory committee. The FDA provides a firm date (April 26, 2023) for its decision concerning approval of SER-109.
  • 11/10/2022

Seres Therapeutics, Inc. (MCRB) Q3 2022 Earnings Call Transcript

  • Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q3 2022 Earnings Conference Call November 2, 2022 8:30 AM ET Company Participants Carlo Tanzi - Head of Investor Relations Eric Shaff - President & Chief Executive Officer Lisa von Moltke - Chief Medical Officer Matthew Henn - Chief Scientific Officer David Arkowitz - Chief Financial Officer Teresa Young - Chief Commercial & Strategy Officer Conference Call Participants Peyton Bohnsack - Cowen Ted Tenthoff - Piper Sandler Mark Breidenbach - Oppenheimer John Newman - Canaccord Operator Good morning. My name is Colby and I will be your conference operator today.
  • 11/02/2022

Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022

  • CAMBRIDGE, Mass.
  • 10/27/2022

Seres Therapeutics to Present Clinical Results at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meeting

  • CAMBRIDGE, Mass.
  • 10/12/2022

Seres Therapeutics: What The Market Is Missing

  • Seres Therapeutics was founded in 2010 at a time when the Human Microbiome Project was “hot”. So Seres was there when microbiomics began to get serious. Nestle Health Science has been an early investor and concluded a major deal on marketing rights in early 2016. The first product, SER-109, is being readied for market.
  • 08/19/2022

Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates

  • Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -20.69% and 79.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
  • 08/03/2022

Seres Therapeutics: The Good And The Challenging

  • Seres' $100 million share placement with strategic partners, including Nestle, helps stabilize the share price. The C. difficile market - how big is it? Who can compete with the Seres/Nestle (Aimmune Therapeutics) global rollout for C. difficile recurrence?
  • 07/12/2022

Seres Therapeutics: The Pipeline Is The Problem

  • SER-109 has shown an excellent efficacy and safety profile but is entering a small and crowded market. SER-287 and SER-301 have shown no efficacy.
  • 06/10/2022

Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens

  • Seres Therapeutics reports new data concerning safety and effectiveness of SER-109 for treating recurrent C.difficile infection. This completes Seres package for BLA (Biologics License Application) to the FDA.
  • 06/09/2022

Seres Therapeutics Touts New Safety Data, Plans First FDA Approval For Microbiome Drug

  • Seres Therapeutics Inc (NASDAQ: MCRB) announced confirmatory results from ECOSPOR IV, an open-label study for SER-109 to prevent recurrent C. difficile infection (rCDI).
  • 06/07/2022

Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q1 2022 Results - Earnings Call Transcript

  • Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Carlo Tanzi - Head of Investor Relations Eric Shaff - President and Chief Executive Officer Lisa von Moltke - Chief Medical Officer Matthew Henn - Chief Scientific Officer David Arkowitz - Chief Financial Officer Terri Young - Chief Commercial and Strategy Officer David Ege - Chief Technology Officer Conference Call Participants Mark Breidenbach - Oppenheimer Peyton Bohnsack - Cowen John Newman - Canaccord Chris Howerton - Jeffries Vernon Bernardino - H.C. Wainwright Operator Welcome to Seres Therapeutics First Quarter 2022 Financial Results Conference Call.
  • 05/04/2022

Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates

  • Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.93% and 79.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
  • 05/04/2022

Destiny Pharma undervalued compared to peers, suggests finnCap

  • Destiny Pharma's 29021 year-end cash of £4.65mln together with a £6.5mln fundraise in March 2022 provides a funding runway into mid-2023, says house broker finnCap. “With several companies active in the NTCD-M3 data room, we look forward to the company securing a partner to co-fund the Phase 3 trial.
  • 04/12/2022

Seres Therapeutics Is Playing A Long Game

  • Seres misses on earnings and revenue, although revenue was up 344% to $144.92 million.
  • 03/06/2022

Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q4 2021 Results - Earnings Call Transcript

  • Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q4 2021 Results - Earnings Call Transcript
  • 03/01/2022

Seres Therapeutics (MCRB) Reports Q4 Loss, Lags Revenue Estimates

  • Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -22.22% and 62.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
  • 03/01/2022

Will The Rally Continue In Seres Therapeutics (MCRB) Stock After A Stellar 77% Surge In A Month?

  • The stock price of Seres Therapeutics, a small late stage clinical biotechnology company with a market cap of around $1 billion, is up a whopping 77% in a month, while it is up 17% over the last week. There were multiple positive developments that supported the stock price growth for Seres.
  • 12/02/2021

Why Shares of Seres Therapeutics Rose More Than 21% on Tuesday

  • The biotech stock announced it had enrolled its first patient in a trial for one of its therapies.
  • 11/30/2021

Seres Therapeutics (MCRB) Stock: Why The Price Surged Today

  • The stock price of Seres Therapeutics Inc (NASDAQ: MCRB) increased by over 20% during intraday trading today. This is why it happened.
  • 11/30/2021

Seres Therapeutics (MCRB) Stock: Why The Price Increased Today

  • The stock price of Seres Therapeutics Inc (NASDAQ: MCRB) slightly increased pre-market today. This is why it happened.
  • 11/24/2021

Seres Therapeutics to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, participated in a pre-recorded fireside chat as part of the Piper Sandler 33rd Annual Virtual Healthcare Conference, which will take place November 29 – December 2, 2021. The fireside chat will be available for on-demand viewing on the Seres website. About Seres Therapeutics Seres Ther
  • 11/24/2021

Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q3 2021 Results - Earnings Call Transcript

  • Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q3 2021 Results - Earnings Call Transcript
  • 11/10/2021

Seres Therapeutics (MCRB) Q3 Earnings and Revenues Beat Estimates

  • Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 253.19% and 1681.10%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
  • 11/10/2021

Red Light For Seres Therapeutics, But Not A Stop Light For Me

  • Red Light For Seres Therapeutics, But Not A Stop Light For Me
  • 11/10/2021

Seres Therapeutics to Host Third Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on November 10, 2021

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on November 10, 2021 at 8:30 a.m. ET to discuss third quarter 2021 results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 1275436. To join the live webcast, please vis
  • 11/04/2021

BiomX: Undervalued With Multiple Upcoming Catalysts

  • BiomX: Undervalued With Multiple Upcoming Catalysts
  • 10/06/2021

Seres Therapeutics Molecular Data On SER-109 Looks Good

  • Seres Therapeutics Molecular Data On SER-109 Looks Good
  • 10/04/2021

Seres Therapeutics Presents Late-Breaking Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at IDWeek2021

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced late-breaking data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapeutic for recurrent C. difficile infection (rCDI). SER-109 was associated with significantly greater reduction of antimicrobial resistance genes (ARGs) compared to placebo, with the reduction observed both rapidly (by Week 1) and sustained through W
  • 10/02/2021

Seres Therapeutics Presents Data Supporting its Microbiome Pipeline at IDWeek 2021, Including Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapy for recurrent C. difficile infection (rCDI), will be presented at the IDWeek 2021 Virtual Conference (Sept. 29-Oct. 3). The Company will be presenting seven posters and oral presentations related to SER-109 and C. difficile, including a late-breaker, as well as
  • 09/29/2021

Why Seres Therapeutics Stock Is Soaring Today

  • The company completed its target enrollment in a pivotal clinical study.
  • 09/15/2021

Why Seres Therapeutics Shares Are Trading Higher Today

  • Seres Therapeutics (NASDAQ:MCRB) shares are trading higher after the company achieved enrollment of 300 subjects in its Phase 3 ECOSPOR IV study of SER-109. Seres Therapeutics' stock has been rising Wednesday, up 17.49% to a price of $6.42.
  • 09/15/2021

Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109, a Potentially First-in-Class Investigational Microbiome Therapeutic for Recurrent C. difficile Infection

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced it has achieved enrollment of 300 subjects with the ECOSPOR IV open-label study evaluating SER-109, an investigational oral microbiome therapeutic for recurrent C. difficile infection (rCDI). The target enrollment of a minimum of 300 subjects for the SER-109 safety database was reached in conjunction with a prior completed Phase 3 study, ECOSPOR lll. Seres is re
  • 09/15/2021

Seres Therapeutics: Here We Go Again

  • The microbiome has arrived as a significant area of opportunity for new treatments of infectious and chronic conditions. While the importance of the microbiome is clear, validated products remain elusive.
  • 09/09/2021

Cathie Wood's ARK Invest Sells Over 840,000 Shares of Seres Therapeutics

  • One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood sold over 840,000 shares of Seres Therapeutics Inc.
  • 08/31/2021

Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q2 2021 Results - Earnings Call Transcript

  • Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q2 2021 Results - Earnings Call Transcript
  • 08/03/2021

Recap: Seres Therapeutics Q2 Earnings

  • Shares of Seres Therapeutics (NASDAQ:MCRB) moved higher by 2.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 89.29% year over year to ($0.53), which missed the estimate of ($0.37).
  • 08/03/2021

Why Seres Therapeutics Stock Is Crashing Today

  • The company reported disappointing results from a phase 2b clinical study.
  • 07/22/2021

MCRB Stock Fell Over 50% Pre-Market: Why It Happened

  • The stock price of Seres Therapeutics Inc (NASDAQ: MCRB) fell by over 50% pre-market. This is why it happened.
  • 07/22/2021

Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative Colitis

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast today at 8:30 a.m. ET to discuss topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC). To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID numbe
  • 07/22/2021

Seres Therapeutics Stock Plunges As Ulcerative Colitis Candidate Disappoints In Mid-Stage Study

  • Seres Therapeutics Inc (NASDAQ: MCRB) has announced topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC).  The study did not meet its primary endpoint of improving clinical remission rates compared to placebo.
  • 07/22/2021

Implied Volatility Surging for Seres Therapeutics (MCRB) Stock Options

  • Investors need to pay close attention to Seres Therapeutics (MCRB) stock based on the movements in the options market lately.
  • 07/07/2021

Forensic Value Stock Selections: Top Positive And Negative Scoring Stocks For Mid-Year 2021

  • Forensic Value Stock Selections: Top Positive And Negative Scoring Stocks For Mid-Year 2021
  • 07/06/2021

Nestlé Bets $525M On Seres Therapeutics Microbiome Drug For Infectious Diseases

  • Seres Therapeutics Inc (NASDAQ: MCRB) has inked a $525-million deal with Nestlé Health Science to commercialize SER-109 if it can win FDA approval. SER-109 is an oral, live microbiome therapy under development for patients with recurrent C.
  • 07/01/2021

Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement

  • CAMBRIDGE, Mass. & LAUSANNE, Switzerland--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it has entered into an agreement with Nestlé Health Science to jointly commercialize SER-109, Seres' investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection (CDI), in the United States (U.S.) and Canada. If approved, SER-109 would become the first-ever FDA-approved microbiome therapeutic. Under th
  • 07/01/2021

Seres Therapeutics Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced data from their collaboration with the University of Cologne (Köln, Germany) demonstrating that decreased microbiome diversity in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is associated with poor clinical outcomes including mortality and increased incidence of intestinal graft-versus-host disease (GvHD). The data are being presented in
  • 06/04/2021

Seres Therapeutics Gets FDA Green Signal to Start SER-155 Human Trials

  • The FDA has signed off  Seres Therapeutics Inc's (NASDAQ: MCRB) Investigational New Drug (IND) application for SER-155 to initiate Phase 1 trial. SER-155 is a cultivated microbiome therapeutic designed to reduce the incidence of gastrointestinal antibiotic-resistant bacterial infections, bacteremia, and graft-versus-host disease (GvHD).
  • 06/01/2021

Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 2021

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced the presentation of its final 24-week data from the pivotal Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapy for recurrent C. difficile infection (rCDI). The data presented today in a poster of distinction at Digestive Disease Week® 2021 demonstrated that SER-109 significantly reduced recurrence rates compared to placebo over 24
  • 05/21/2021

Seres Therapeutics to Present Clinical Research on the Microbiome's Impact on Allogeneic Hematopoietic Stem Cell Transplantation and Cancer Immunotherapy at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it will present the latest research from its early stage clinical development programs in two presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually from June 4-8, 2021. In an oral presentation, Seres will share data from its collaboration with the University of Cologne (Köln, Germany) assessing the associat
  • 05/19/2021

Seres Therapeutics' SER-287 Is Likely To Succeed In Its Phase 2b Trial

  • Fecal microbiota transplantation has succeeded in various randomized ulcerative colitis trials.
  • 03/18/2021

Seres Therapeutics to Present at the 31st Annual Oppenheimer Healthcare Conference

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, announced that managment will present a corporate overview at the 31st Annual Oppenheimer Healthcare Conference on Tuesday, March 16 at 9:20 a.m. ET. A live audio webcast of the presentation will be available under the “Investors and Media” section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived
  • 03/12/2021

Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q4 2020 Results - Earnings Call Transcript

  • Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q4 2020 Results - Earnings Call Transcript
  • 03/02/2021

Seres Therapeutics (MCRB) Reports Q4 Loss, Tops Revenue Estimates

  • Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 30.77% and 99.98%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
  • 03/02/2021

Seres Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updates

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2020 financial results and provided business updates. “Seres continues to make progress executing against our top corporate priorities. We are enrolling our open label study to support a Biologics License Application (BLA) for SER-109, a potential first-ever FDA approved microbiome therapeutic. We have also advanced our clinical pipe
  • 03/02/2021

Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will participate in two upcoming investor conferences: Cowen 41st Annual Health Care Conference on Tuesday, March 2, 2021. Management will participate in a Microbiome panel discussion as well as 1x1 meetings. Chardan 3rd Annual Microbiome Medicines Summit on Monday, March 8, 2021. Management will present a corporate overview at 2:30 p.m. ET and
  • 02/26/2021

Earnings Preview: Seres Therapeutics (MCRB) Q4 Earnings Expected to Decline

  • Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  • 02/22/2021

4D Pharma: Impressive Immuno-Oncology Data

  • 4D Pharma: Impressive Immuno-Oncology Data
  • 02/16/2021

Seres Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 11:40 a.m. ET. A live audio webcast of the presentation will be available under the “Investors and Media” section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days. About Seres Therapeutics Sere
  • 01/06/2021

5 Medical Outperformers That Might Lose Steam in 2021

  • Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.
  • 12/22/2020

These Were the 10 Best Healthcare Stocks of 2020

  • The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?
  • 12/15/2020

These 5 Mid-Cap Healthcare Stocks Had the Best Gains in 2020

  • Investors favored coronavirus vaccine work, late-stage trial victories, and genetic sequencing.
  • 12/11/2020

Seres Therapeutics: Microbiomics Back In The Game

  • Late August spike means share price moves from below $5 to more than $30. Capital raising and Nestle agreement raised $264 million.
  • 11/13/2020

Seres Therapeutics' SER-109 Has Accelerated Growth Potential

  • Seres has seen +863% upside YTD on the back of positive top-line data in their phase 3 SER-109 study, which helps prove their microbiome hypotheses. Management have strengthened the cash position and the balance sheet, with key collaborations with Nestle and via equity capital, thus runaway is now over 2 years.
  • 11/12/2020

Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q3 2020 Results - Earnings Call Transcript

  • Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q3 2020 Results - Earnings Call Transcript
  • 11/09/2020

Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it has dosed the first patient in its Phase 1b trial evaluating SER-301 for the treatment of active mild-to-moderate ulcerative colitis (UC). SER-301 is an oral, rationally-designed microbiome therapeutic designed to dampen the aberrant gastrointestinal inflammation central to ulcerative colitis and induce clinical remission in patients suffering from active UC. SER-301 is designed to modify the gast
  • 11/06/2020

Applied Underwriters Sues California Over 'Bad Faith' Insurer Conservatorship Plan

  • Workers' compensation specialist Applied Underwriters is suing California Insurance Department officials to halt a state plan its says would force its
  • 10/21/2020

Computer Design & Integration LLC (CDI LLC) Announces the Promotion of Rich Falcone to President

  • CDI announces the promotion of Rich Falcone to President, with increased responsibilities in M&A efforts, sales expansion and marketing activities.
  • 10/20/2020

Human Microbiome Therapeutics Market In-deep Analysis And Experts Review Report 2020- Enterome Bioscience, Rebiotix, Seres Therapeutics, Vedanta Biosciences, Bristol-Myers Squibb

  • Oct 07, 2020 (Market Insight Reports) -- The Global Human Microbiome Therapeutics Market report provides an in-depth analysis of the key market insights, its...
  • 10/07/2020

Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303, a Defined Bacterial Consortium for Prevention of C. difficile Infection in High-Risk Patients

  • Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303
  • 09/30/2020

Crédit immobilier : ces acheteurs dont les dossiers sont bloqués par manque d’épargne

  • Pas d’assouplissement en vue dans l’obtention du crédit immobilier ! Mi-septembre, le Haut Conseil de Stabilité Financière a confirmé son tour de vis. Les primo-accédants, dont voici quelques profils-types,
  • 09/26/2020

Churchill Downs Incorporated Statement on Kentucky Supreme Court Ruling Regarding the Exacta System Used in Historical Horse Racing Machines

  • Churchill Downs Incorporated (“CDI”) (Nasdaq: CHDN) released today the following statement regarding the Kentucky Supreme Court ruling on the Exacta system used
  • 09/24/2020

CPSI Announces Partnership With ChartWise Medical Systems to Offer Enhanced TruBridge Clinical Documentation Solutions to Improve Reimbursement, Compliance and Quality Scores for Providers

  • CPSI (NASDAQ: CPSI), a healthcare solutions company, and ChartWise Medical Systems Inc. (ChartWise), a computer-assisted clinical document improvement
  • 09/23/2020

Computer Design & Integration LLC (CDI LLC) Acquires ServiceNow Elite Partner, P5 Solutions, Inc. | | IT Business Net

  • Acquisition unites two ServiceNow Elite partners to create global digital transformation powerhouse NEW YORK--(BUSINESS WIRE)--#acquisition--Computer Design & Integration LLC ("CDI" or &
  • 09/22/2020

Computer Design & Integration LLC (CDI LLC) Acquires ServiceNow Elite Partner, P5 Solutions, Inc.

  • Computer Design & Integration LLC (CDI LLC) announces today that it has acquired ServiceNow Elite Partner, P5 Solutions, Inc. (“P5”).
  • 09/22/2020

Ibiuna aposta contra o dólar com riscos menores, mas não larga hedges

  • Para a gestora Ibiuna, economia entra em uma terceira fase da crise, com menos riscos do que antes. Clique aqui para ler mais sobre.
  • 09/20/2020

National Institutes of Health Commissions PhysIQ to Develop COVID-19 Digital Biomarker

  • The National Cancer Institute (NCI) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health (
  • 09/16/2020

Computer Design & Integration LLC (CDI LLC) Announces the Promotion of Cyrus Lam to Chief Financial Officer

  • CDI announces that Cyrus Lam has been promoted to Chief Financial Officer (CFO), now responsible for the Company's overall financial operations.
  • 09/15/2020

GAN Announces New Tier One Client Churchill Downs in Multistate Roll-out of Real Money Internet Gambling

  • GAN Limited (the “Company” or “GAN”) (NASDAQ: GAN), a leading business-to-business supplier of internet gambling software-as-a-service solutions to th
  • 08/27/2020

Conseil fédéral suisse : Le Conseil fédéral adopte les messages relatifs à la nouvelle convention contre les doubles impositions avec Bahreïn et aux modifications de la CDI avec le Koweït

  • 08/26/2020

De Lille à Nice, ces 100 entreprises recrutent malgré la crise

  • Petites ou grandes, elles ont su dépasser la crise, voire parfois en profiter. Dans la foulée, elles prévoient des dizaines de milliers de créations de postes., En ces temps de plans sociaux et de gel
  • 08/26/2020

146th Kentucky Derby to Run on September 5th without Fans

  • Churchill Downs Incorporated (“CDI”) (Nasdaq: CHDN) announced today its decision to run the 146th Kentucky Derby on September 5, 2020 without fans. CDI issued
  • 08/21/2020

Benzinga's Top Upgrades, Downgrades For August 18, 2020

  • Upgrades * Wedbush upgraded the previous rating for Best Buy Co Inc (NYSE: BBY) from Neutral to Outperform. For the first quarter, Best Buy Co had an EPS of $0.67, compared to year-ago quarter EPS of $1.02. At the moment, the stock has a 52-week-high of $111.39 and a 52-week-low of $48.10. Best Buy Co closed at $110.77 at the end of the last trading period. * Cantor Fitzgerald upgraded the previous rating for Curaleaf Holdings Inc (OTC: CURLF) from Neutral to Overweight. Curaleaf Holdings earned $0.03 in the first quarter, compared to $0.02 in the year-ago quarter. The current stock performance of Curaleaf Holdings shows a 52-week-high of $9.66 and a 52-week-low of $2.54. Moreover, at the end of the last trading period, the closing price was at $9.43. * For Barings BDC Inc (NYSE: BBDC), Keefe, Bruyette & Woods upgraded the previous rating of Market Perform to the current rating Outperform. For the second quarter, Barings BDC had an EPS of $0.14, compared to year-ago quarter EPS of $0.15. At the moment, the stock has a 52-week-high of $10.59 and a 52-week-low of $4.67. Barings BDC closed at $8.30 at the end of the last trading period. * Downgrades * According to Argus Research, the prior rating for Howmet Aerospace Inc (NYSE: HWM) was changed from Buy to Hold. Howmet Aerospace earned $0.12 in the second quarter, compared to $0.58 in the year-ago quarter. At the moment, the stock has a 52-week-high of $18.99 and a 52-week-low of $9.87. Howmet Aerospace closed at $17.35 at the end of the last trading period. * For AMAG Pharmaceuticals Inc (NASDAQ: AMAG), Barclays downgraded the previous rating of Overweight to the current rating Equal-Weight. AMAG Pharmaceuticals earned $0.57 in the second quarter, compared to $1.14 in the year-ago quarter. The stock has a 52-week-high of $13.53 and a 52-week-low of $4.41. At the end of the last trading period, AMAG Pharmaceuticals closed at $10.89. * Oppenheimer downgraded the previous rating for Intercontinental Exchange Inc (NYSE: ICE) from Outperform to Perform. For the second quarter, Intercontinental Exchange had an EPS of $1.07, compared to year-ago quarter EPS of $0.94. The current stock performance of Intercontinental Exchange shows a 52-week-high of $104.30 and a 52-week-low of $63.51. Moreover, at the end of the last trading period, the closing price was at $104.07. * For Montage Resources Corp (NYSE: MR), Johnson Rice downgraded the previous rating of Buy to the current rating Hold. At the moment, the stock has a 52-week-high of $8.30 and a 52-week-low of $1.99. Montage Resources closed at $5.51 at the end of the last trading period. * According to Citigroup, the prior rating for Nabors Industries Ltd (NYSE: NBR) was changed from Neutral to Sell. For the second quarter, Nabors Industries had an EPS of $14.45, compared to year-ago quarter EPS of $0.41. At the moment, the stock has a 52-week-high of $87.00 and a 52-week-low of $0.20. Nabors Industries closed at $46.45 at the end of the last trading period. * For Unity Biotechnology Inc (NASDAQ: UBX), Morgan Stanley downgraded the previous rating of Overweight to the current rating Equal-Weight. Unity Biotechnology earned $0.38 in the second quarter, compared to $0.56 in the year-ago quarter. At the moment, the stock has a 52-week-high of $15.44 and a 52-week-low of $4.05. Unity Biotechnology closed at $4.15 at the end of the last trading period. * Morgan Stanley downgraded the previous rating for Vonage Holdings Corp (NASDAQ: VG) from Overweight to Equal-Weight. Vonage Hldgs earned $0.04 in the second quarter, compared to $0.08 in the year-ago quarter. The current stock performance of Vonage Hldgs shows a 52-week-high of $13.66 and a 52-week-low of $4.18. Moreover, at the end of the last trading period, the closing price was at $11.77. * SVB Leerink downgraded the previous rating for Principia Biopharma Inc (NASDAQ: PRNB) from Outperform to Market Perform. The current stock performance of Principia Biopharma shows a 52-week-high of $99.38 and a 52-week-low of $25.35. Moreover, at the end of the last trading period, the closing price was at $99.25. Initiations * With a current rating of Outperform, Wedbush initiated coverage on Inozyme Pharma Inc (NASDAQ: INZY). The price target seems to have been set at $35.00 for Inozyme Pharma. The current stock performance of Inozyme Pharma shows a 52-week-high of $31.27 and a 52-week-low of $17.25. Moreover, at the end of the last trading period, the closing price was at $29.00. * Needham initiated coverage on Nurix Therapeutics Inc (NASDAQ: NRIX) with a Buy rating. The price target for Nurix Therapeutics is set to $35.00. The current stock performance of Nurix Therapeutics shows a 52-week-high of $27.64 and a 52-week-low of $15.21. Moreover, at the end of the last trading period, the closing price was at $27.00. * Brookline Capital initiated coverage on 9 Meters Biopharma Inc (NASDAQ: NMTR) with a Buy rating. The price target for 9 Meters Biopharma is set to $5.00. 9 Meters Biopharma earned $0.57 in the second quarter, compared to $0.13 in the year-ago quarter. The stock has a 52-week-high of $0.82 and a 52-week-low of $0.44. At the end of the last trading period, 9 Meters Biopharma closed at $0.56. * JP Morgan initiated coverage on ITeos Therapeutics Inc (NASDAQ: ITOS) with an Overweight rating. The price target for ITeos Therapeutics is set to $40.00. At the moment, the stock has a 52-week-high of $32.98 and a 52-week-low of $17.50. ITeos Therapeutics closed at $32.92 at the end of the last trading period. * With a current rating of Buy, Citigroup initiated coverage on Digital Media Solutions Inc (NYSE: DMS). The price target seems to have been set at $12.00 for Digital Media Solutions. At the moment, the stock has a 52-week-high of $10.66 and a 52-week-low of $6.75. Digital Media Solutions closed at $8.41 at the end of the last trading period. * With a current rating of Buy, B of A Securities initiated coverage on Annexon Inc (NASDAQ: ANNX). The price target seems to have been set at $33.00 for Annexon. The stock has a 52-week-high of $29.71 and a 52-week-low of $15.33. At the end of the last trading period, Annexon closed at $26.55. * Wells Fargo initiated coverage on Voya Financial Inc (NYSE: VOYA) with an Overweight rating. The price target for Voya Finl is set to $62.00. For the second quarter, Voya Finl had an EPS of $1.09, compared to year-ago quarter EPS of $1.52. The stock has a 52-week-high of $63.81 and a 52-week-low of $29.75. At the end of the last trading period, Voya Finl closed at $51.22. * B of A Securities initiated coverage on Inozyme Pharma Inc (NASDAQ: INZY) with a Buy rating. The price target for Inozyme Pharma is set to $33.00. At the moment, the stock has a 52-week-high of $31.27 and a 52-week-low of $17.25. Inozyme Pharma closed at $29.00 at the end of the last trading period. * For Annexon Inc (NASDAQ: ANNX), Cowen & Co. initiated coverage, by setting the current rating at Outperform. The current stock performance of Annexon shows a 52-week-high of $29.71 and a 52-week-low of $15.33. Moreover, at the end of the last trading period, the closing price was at $26.55. * With a current rating of Overweight, Piper Sandler initiated coverage on ITeos Therapeutics Inc (NASDAQ: ITOS). The price target seems to have been set at $50.00 for ITeos Therapeutics. The current stock performance of ITeos Therapeutics shows a 52-week-high of $32.98 and a 52-week-low of $17.50. Moreover, at the end of the last trading period, the closing price was at $32.92. * Piper Sandler initiated coverage on Seres Therapeutics Inc (NASDAQ: MCRB) with an Overweight rating. The price target for Seres Therapeutics is set to $40.00. In the second quarter, Seres Therapeutics showed an EPS of $0.28, compared to $0.24 from the year-ago quarter. At the moment, the stock has a 52-week-high of $33.00 and a 52-week-low of $2.52. Seres Therapeutics closed at $26.16 at the end of the last trading period. * Needham initiated coverage on Personalis Inc (NASDAQ: PSNL) with a Buy rating. The price target for Personalis is set to $25.00. For the second quarter, Personalis had an EPS of $0.29, compared to year-ago quarter EPS of $0.89. The stock has a 52-week-high of $23.00 and a 52-week-low of $4.27. At the end of the last trading period, Personalis closed at $21.72.See more from Benzinga * Forward Industries: Debt Overview * Agilent's Debt Overview * Kohl's's Debt Overview(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
  • 08/18/2020

A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Walmart Earnings

  • Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade, as investors are awaiting earnings from Walmart Inc (NYSE: WMT), Advance Auto Parts, Inc. (...
  • 08/18/2020

Seres Therapeutics, Inc. Announces Closing of Public Offerings of 12,075,000 Shares of Common Stock

  • Seres Therapeutics, Inc. today announced the closing of an underwritten public offering of 12,075,000 shares of its common stock.
  • 08/17/2020

Why Seres Therapeutics Stock Surged Today

  • What happened Shares of Seres Therapeutics (NASDAQ: MCRB) jumped 21% on Thursday after the biotech company announced the details of its capital raise.  So what Seres will sell 10.5 million shares for $21.
  • 08/13/2020

Evogene: Hidden Gems Of Computational Predictive Biology, Part 1 Of 4 (Biomica, Microbiome Therapeutics)

  • Evogene Ltd. has developed a unique Computational Predictive Biology platform, leveraging big data and artificial intelligence to life-science products such as microbes, small molecules and genes.
  • 08/13/2020

Seres Therapeutics, Inc. Announces Pricing of Public Offering of 10,500,000 Shares of Common Stock

  • Seres Therapeutics, Inc. today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock.
  • 08/13/2020

Seres Therapeutics up by 390% in a Day; This Analyst Sees More Upside in the Cards

  • To say Seres Therapeutics (MCRB) began the week with a bang would be a severe understatement. More like an earth-shattering explosion. Shares surged by 390% in Monday’s trading after the microbiome drug maker announced positive results from a clinical trial.In a Phase 3 study of SER-109 for the treatment of recurrent C. difficile infection (CDI), the oral microbiome medicine exhibited a 30.2% drop in the proportion of patients who experienced a recurrence in CDI within an eight week period compared to placebo. Overall, only 11.1% of patients given the treatment experienced a CDI recurrence as opposed to 41.3% in the control arm.Oppenheimer analyst Mark Breidenbach is in no doubt as to the importance of the results and the impact they could have on the colon infection therapy’s success.“These results are the most compelling we have seen for any microbiome restoration therapy to date, and represent a major vindication for Seres’ platform technology and rational approach to study design,” Breidenbach said, further adding, “In our view, the 30.2% absolute lower recurrence rate with SER-109 is clearly an unprecedented win from an efficacy standpoint, and we increase our POS to 90% (vs. prior 50%).”Next up, Seres will schedule a meeting with the FDA to finalize registrational requirements, including safety database size. Breidenbach believes the results could “put the company on track for a 2021 filing.”Along with increasing the therapy’s chances of success, the analyst increased his US and EU peak sales estimates from $100 million to $600 million. Moreover, since the trial de-risked Seres’ core platform technology, the 5-star analyst increased the possibility of success for Seres’ ulcerative colitis candidate SER-287 (currently in a Phase 2b study) from 30% to 50%.To this end, Breidenbach reiterates an Outperform (i.e. Buy) rating on MCRB shares, while giving his price target a massive boost – up from $7 to $30. Even after Monday's surge, the figure represents possible upside of an additional 50%. (To watch Breidenbach’s track record, click here)All in all, Breidenbach’s colleagues concur. Based on 6 Buy ratings with no Holds or Sells, Seres has a Strong Buy consensus rating. Meanwhile, the $34.10 average price target represents possible of 70%. (See Seres stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
  • 08/11/2020

Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

  • Seres Therapeutics, Inc. today announced that it is commencing an underwritten registered public offering of 8,000,000 shares of its common stock.
  • 08/11/2020

Seres Jumps On Data, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:MCRB)

  • Seres Therapeutics stock jumps on positive topline data. Humanigen expands Lenzilumab study in Brazil.
  • 08/11/2020

Seres Therapeutics (NASDAQ:MCRB) Upgraded by ValuEngine to Buy

  • Seres Therapeutics (NASDAQ:MCRB) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Tuesday, ValuEngine reports. Several other brokerages have also commented on MCRB. BidaskClub lowered Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, July 18th. Oppenheimer […]
  • 08/11/2020

Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

  • Seres Therapeutics, Inc. today announced that it is commencing an underwritten registered public offering of 8,000,000 shares of its common stock.
  • 08/11/2020

Chardan Capital Sticks to Its Buy Rating for Seres Therapeutics (MCRB) - Markets

  • Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Seres Therapeutics (MCRB – Research Report) today and set a
  • 08/10/2020

Juros reais negativos: como você deve investir com uma inflação acima do CDI

  • Nova realidade deve levar investidor a buscar mais risco na alocação de renda fixa, ainda que reserva de emergência seja penalizada
  • 08/10/2020

Why Seres Therapeutics Stock Skyrocketed 350% Today

  • Shares of Seres Therapeutics (NASDAQ: MCRB) soared on Monday after the biotech company announced promising results from a phase 3 study of its experimental therapy for colon infections. Seres said the administration of its oral microbiome therapeutic, labeled SER-109, resulted in a 30.2% decline in the number of patients who experienced a recurrence of C. difficile infection (CDI) within an eight-week period, compared to a placebo. Seres Therapeutics' stock rocketed higher on Monday.
  • 08/10/2020

Seres Therapeutics Stock Scales Nasdaq on Positive Drug Data

  • The stock hit a four-year high earlier in the day
  • 08/10/2020

Return On Capital Employed Overview: Seres Therapeutics

  • During Q2, Seres Therapeutics (NASDAQ: MCRB) reported sales totaled $6.04 million. Despite a 4.33% in earnings, the company posted a loss of $20.55 million. In Q1, Seres Therapeutics brought in $8.19 million in sales but lost $19.69 million in earnings.Why ROCE Is Significant Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed in a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth in a company and is a sign of higher earnings per share for shareholders in the future. A low or negative ROCE suggests the opposite. In Q2, Seres Therapeutics posted an ROCE of 0.31%.Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.View more earnings on MCRBROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Seres Therapeutics is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will lead to higher returns and earnings per share growth.In Seres Therapeutics's case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions.Q2 Earnings Insight Seres Therapeutics reported Q2 earnings per share at $-0.28/share, which did not meet analyst predictions of $-0.26/share.See more from Benzinga * Stocks That Hit 52-Week Highs On Monday * Morning Market Stats in 5 Minutes * Recap: Seres Therapeutics Q2 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
  • 08/10/2020

This Tiny Biotech's Shares Quadruple After Late-Stage Drug Tests Succeed

  • Seres Therapeutics early Monday announced Phase 3 success with its study of a treatment for a potentially fatal colon disease treatment, sending MCRB stock quadrupling in early trading.
  • 08/10/2020

Seres Therapeutics stock rockets nearly fourfold after positive Phase 3 data on treatment for colon infections

  • Shares of Seres Therapeutics Inc. undefined rocketed nearly fourfold (up 270%) on heavy volume in premarket trading Monday, after the microbiome therapeutics...
  • 08/10/2020

Seres Therapeutics stock rockets nearly fourfold after positive Phase 3 data on treatment for colon infections

  • Shares of Seres Therapeutics Inc. rocketed nearly fourfold (up 270%) on heavy volume in premarket trading Monday, after the microbiome therapeutics company reported upbeat results of a Phase 3 trial of its SER-109 for recurrent C. difficile infections (CDI), or an infection of the colon. Trading volume ballooned to 7.1 million shares, compared with the full-day average of about 876,000 shares. Seres said the study showed that SER-109 resulted in a "highly statistically significant absolute decrease" in the proportion of patients who experienced a recurrence in CDI within 8 weeks of administration versus placebo. ""We are extremely pleased with these highly clinically meaningful SER-109 Phase 3 study results, greatly exceeding the statistical threshold provided by the [Food and Drug Administration]," said Chief Executive Eric Shaff. "Based on our prior discussions with the FDA, we believe this trial should provide the efficacy basis for submitting an application for product approval." The stock has rallied 34.5% year to date through Friday, while the iShares Nasdaq Biotechnology ETF has advanced 13.0% and the S&P 500 has gained 3.7%.
  • 08/10/2020

Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection

  • SER-109 met Phase 3 primary endpoint, showing highly statistically significant 30.2% absolute reduction in the rate of C. diff infection recurrence.
  • 08/10/2020

Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection

  • SER-109 met Phase 3 primary endpoint, showing highly statistically significant 30.2% absolute reduction in the rate of C. diff infection recurrence.
  • 08/10/2020

Banco de Chile (BCH) Q2 2020 Results - Earnings Call Transcript

  • Banco de Chile (NYSE:BCH) Q2 2020 Earnings Conference Call August 07, 2020, 12:30 PM ET Company Participants Rodrigo Aravena - Chief Economist and Senior Vice President of Institutional Relations Pablo Mejia - Head of IR Daniel Galarce - Head of Financial Control Conference Call Participants Ernesto Gabilondo - Bank of America Claudia Benavente - Santander Sebastián Gallego - CrediCorp Capital Neha Agarwala - HSBC Alonso Garcia - Credit Suisse Presentation Operator Hello, everyone, and welcome to Banco de Chile's 2Q '20 Financial Results Conference Call.
  • 08/07/2020

Do Options Traders Know Something About Seres Therapeutics (MCRB) Stock We Don't?

  • Investors need to pay close attention to Seres Therapeutics (MCRB) stock based on the movements in the options market lately.
  • 08/07/2020

Rhône-Alpes : comment ces 25 patrons continuent d'embaucher

  • Capital a sondé pour vous les entreprises de la région Rhône-Alpes. En voici 25 qui, après avoir souvent adapté leur activité pendant le confinement, envisagent la reprise de leur développement en termes
  • 08/06/2020

Seres Therapeutics Inc (NASDAQ:MCRB) Holdings Cut by Sumitomo Mitsui Trust Holdings Inc.

  • Sumitomo Mitsui Trust Holdings Inc. decreased its stake in Seres Therapeutics Inc (NASDAQ:MCRB) by 12.1% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,400,245 shares of the biotechnology company’s stock after selling 1,018,075 shares during the quarter. Sumitomo Mitsui Trust […]
  • 08/03/2020

Seres Therapeutics (NASDAQ:MCRB) Downgraded by Zacks Investment Research

  • Zacks Investment Research downgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a buy rating to a sell rating in a research note released on Thursday, Zacks.com reports. According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is […]
  • 08/03/2020

Research Analysts Offer Predictions for Seres Therapeutics Inc’s FY2020 Earnings (NASDAQ:MCRB)

  • Seres Therapeutics Inc (NASDAQ:MCRB) – Stock analysts at Jefferies Financial Group issued their FY2020 earnings estimates for Seres Therapeutics in a research note issued on Tuesday, July 28th. Jefferies Financial Group analyst C. Howerton expects that the biotechnology company will post earnings per share of ($0.22) for the year. Jefferies Financial Group also issued estimates […]
  • 08/02/2020

Janus Henderson : Dividend/Distribution - JHG | MarketScreener

  • 07/29/2020

Comment rédiger un CDI ?

  • La conclusion d’un contrat de travail à durée indéterminée demeure la forme typique et générale de la relation de travail., A cet égard, la rédaction d’un contrat de travail à durée indéterminée diffère
  • 07/29/2020

Earnings Preview: Seres Therapeutics (MCRB) Q2 Earnings Expected to Decline

  • Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  • 07/28/2020

Recap: Seres Therapeutics Q2 Earnings

  • Shares of Seres Therapeutics (NASDAQ:MCRB) fell 6.4% after the company reported Q2 results.Quarterly Results Earnings per share decreased 16.67% over the past year to ($0.28), which missed the estimate of ($0.26).Revenue of $6,045,000 declined by 51.76% year over year, which missed the estimate of $9,540,000.Outlook Earnings guidance hasn't been issued by the company for now.View more earnings on MCRBSeres Therapeutics hasn't issued any revenue guidance for the time being.Technicals 52-week high: $6.75Company's 52-week low was at $2.15Price action over last quarter: down 8.70%Company Description Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.See more from Benzinga * 17 Healthcare Stocks Moving In Monday's Pre-Market Session * Stocks That Hit 52-Week Highs On Wednesday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
  • 07/28/2020

Seres Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates

  • Topline data from SER-109 Phase 3 study in recurrent C. difficile infection expected in August 2020; pipeline of other promising candidates advancing.
  • 07/28/2020

How are the Stock Market, Earthquakes, and Disease Related?

  • Predicting the spread of infections using time series data, with techniques traditionally applied to model financial trends
  • 07/28/2020

Debêntures: aprenda como investir nesses títulos de renda fixa

  • As debêntures títulos de renda fixa de crédito privado que normalmente possuem maior rentabilidade. Clique e saiba como investir em debêntures.
  • 07/27/2020

The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings

  • Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks. Although there were promising updates from...
  • 07/26/2020

Chute «historique» des embauches au second trimestre en France

  • Après plusieurs mois de baisse spectaculaire, les embauches se reprennent en mai et juin. Le bilan du trimestre reste inquiétant.
  • 07/22/2020

En quoi va consister l'aide à l'embauche des jeunes promise par le gouvernement ?

  • Jusqu'ici, la piste privilégiée était une « exonération de charges » salariales mais il n'est pas exclu que l'aide prenne finalement la forme d'une prime. En baissant le coût du travail, l'exécutif espère inciter les entreprises à recruter des jeunes. Aux dernières nouvelles, il aurait calibré son aide à hauteur de 4.000 euros pour les moins de 25 ans jusqu'à 1,6 SMIC, soit 2.460 euros bruts.
  • 07/21/2020

Apesar da Selic em piso histórico, gestoras de multimercados resistem a reduzir famosa taxa "2% com 20%"

  • Levantamento revela que apenas dois de 76 fundos reduziram a cobrança durante o primeiro semestre de 2020
  • 07/20/2020

Com 920 mil novos cotistas no 1º semestre, fundos de renda fixa perdem para o CDI e cobram até 1,75% ao ano

  • Entre os 20 fundos de renda fixa com maior entrada de cotistas entre janeiro e junho, 15 perderam para o CDI, mostra levantamento do InfoMoney
  • 07/19/2020

California Department of Insurance Investigation Leads to $5.5M Settlement

  • A settlement has been announced between Libre by Nexus Inc. in which it will cease transacting immigration bonds in the California, phase out the use of
  • 07/16/2020

DEINOVE: DNV3837 Antibiotic Candidate: the Phase II Trial Continues in the United States, Despite a Disrupted Context Due to The COVID-19 Outbreak

  • Regulatory News: DEINOVE (Paris:ALDEI) (Euronext Growth Paris: ALDEI), a French biotech company that uses its lead generation platform to develop inno
  • 07/15/2020

RPS Capital vê investidor maduro e oferece filosofia diferente | InfoMoney

  • RPS Capital: a Gestora investida pelos principais Family Offices do país abre ao varejo fundos de ações descorrelacionados para diferentes
  • 07/14/2020

Seres Therapeutics (NASDAQ:MCRB) Upgraded to “Buy” by Zacks Investment Research

  • Seres Therapeutics (NASDAQ:MCRB) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Tuesday, Zacks.com reports. The brokerage currently has a $5.00 price target on the biotechnology company’s stock. Zacks Investment Research‘s price objective indicates a potential upside of 19.47% from the stock’s previous close. […]
  • 07/14/2020

ICIS gibt die Übernahme von Chemical Data (CDI) bekannt

  • ICIS, Teil von RELX, gab heute die Übernahme von Chemical Data, LLC (CDI), einem führenden Anbieter von US-Preis-Benchmarks für petrochemische Produkte, Marktanalysen und vorausschauende Analysen mit …
  • 07/13/2020

ICIS : Announces It Has Acquired Chemical Data (CDI)

  • 07/13/2020

Australian fintech firm Sezzle raises A$79.1m via institutional placement - FinanceFeeds

  • Proceeds will be used to accelerate Sezzle’s growth strategy and strengthen its balance sheet.
  • 07/13/2020

Stocks To Watch: Bank Earnings And SPAC Deals Blaze In

  • Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
  • 07/11/2020

Fintech firm Sezzle launches A$86.3m capital raising to propel growth strategy - FinanceFeeds

  • The capital raising includes an institutional placement to raise A$79.1 million, followed by a non-underwritten Security Purchase Plan that aims to raise approximately A$7.2 million.
  • 07/10/2020

The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio

  • Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Akero Therapeutics Inc (...
  • 07/09/2020

Seres Therapeutics (MCRB) in Focus: Stock Moves 10.8% Higher

  • Seres Therapeutics (MCRB) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
  • 07/08/2020

Computer Design & Integration LLC (CDI LLC) Acquires Plan B Technologies, Inc. | | IT Business Net

  • Investment allows firm to expand service offerings and geographical reach NEW YORK--(BUSINESS WIRE)--#cloud--Computer Design & Integration LLC ("CDI" or "the Company") announce
  • 07/07/2020

Implied Volatility Surging for Seres Therapeutics (MCRB) Stock Options

  • Investors need to pay close attention to Seres Therapeutics (MCRB) stock based on the movements in the options market lately.
  • 07/07/2020

Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing

  • Flagship Pioneering today announced the unveiling of Tessera Therapeutics, Inc. a new company with the mission of curing disease by writing in the code of life. Tessera is pioneering Gene Writing™, a new biotechnology that writes therapeutic messages into the genome to treat diseases at their source.
  • 07/07/2020

Computer Design & Integration LLC (CDI LLC) Acquires Plan B Technologies, Inc.

  • CDI announces that it has acquired Plan B Technologies, Inc., an IT solutions and professional services provider serving clients in the Mid-Atlantic.
  • 07/07/2020

Garmin® GI 275 electronic flight instrument CDI/MFD ready for helicopter installations

  • Garmin International today announced that the GI 275 is ready for installation in select Part 27 FAA registered helicopters via Field Approval.
  • 07/06/2020

« Obtenir un emploi stable prend de plus en plus d’années » : les jeunes journalistes, toujours plus précaires

  • Le secteur fait face en ce moment à des difficultés accrues, qui rendent l’insertion sur le marché du travail encore plus incertaine pour les jeunes diplômés. Certains décident de changer de voie.
  • 07/02/2020

Dott, l'opérateur de trottinettes électriques, célèbre un million de trajets à Bruxelles

  • En deux mois, plus de 3 000 trajets ont été offerts au personnel soignant.
  • 07/02/2020

Offres d’emploi du Forem en Wallonie picarde

  • Voici les offres d’emploi du jour, offres accessibles à tous sans discrimination.
  • 07/02/2020

A l’hôpital de Valenciennes, la prime Covid19 “dérisoire” des salariés d’Onet

  • Des agents de propreté d'Onet, sous-traitant de l'hôpital de Valenciennes, sont en grève. Ils dénoncent une prime Covid19 de misère, "dérisoire" au vu de celle des personnels soignants, alors
  • 07/02/2020

Grève des salariés d'un sous-traitant de l'hôpital de Valenciennes, pour une «vraie prime Covid»

  • 07/02/2020

les Renault de Choisy, du collectif dans le moteur

  • La direction de la marque au losange, qui a annoncé la suppression de 4 000 emplois en France, prétend fermer l’usine de Choisy-le-Roi (94), riche d’une histoire de 70 ans. Forts d’un remarquable savoir-faire, les salariés, plus soudés que jamais, sont entrés en lutte. Et ils ne sont pas seuls.
  • 07/01/2020

California Commissioner Launches Diversity Initiative, Names COIN Board Members

  • California Insurance Commissioner Ricardo Lara on Wednesday announced the launched an "Invest in Our Diverse Communities" initiative to identify diverse
  • 07/01/2020

Congé paternité de 4 semaines, aide à l’embauche des seniors… ces pistes choc pour lutter contre les discriminations au travail

  • Le Conseil d’analyse économique vient de faire une série de recommandations pour réduire les discriminations sur le marché du travail. Certaines d’entre elles risquent de faire réagir. , Un véritable
  • 07/01/2020

Tesouro direto: títulos públicos têm queda de até 15,8% no semestre; confira onde estão as oportunidades agora

  • Principais apostas recaem sobre papéis com retornos indexados à inflação cujas taxas aumentaram na primeira metade do ano
  • 07/01/2020

In Tangle the missteps of parents are mirrored in their offspring

  • Available for the first time on a free streaming service, this accomplished local drama has lost none of its urgency or bitter-sweet poignancy.
  • 07/01/2020

Ibovespa termina o semestre com queda de 17,8%, mas tem melhor trimestre desde 2003; dólar sobe 35,6% no ano

  • Mercado termina um semestre histórico com perdas
  • 06/30/2020

Janssen Korea Ltd. and Johnson & Johnson Innovation Announce Launch of Seoul Innovation QuickFire Challenge for Healthcare in the New Normal in Collaboration with Seoul Metropolitan Government and Korea Health Industry Development Institute

  • 06/30/2020

Michelin versera 3,7 millions d'euros pour l'emploi en Vendée suite à la fermeture de son usine

  • 06/30/2020

Descascar empresas como cebolas: conheça o processo do XP Long Term Equity

  • Rodrigo Furtado, do XP Long Term Equity, contou para o Coffee & Stocks como o processo de descascar cebolas se assemelha com o da análise de empresas
  • 06/30/2020

XP Investimentos starts selling Hashdex fund with exposure to cryptocurrencies - OBN

  • Photo: Shutterstock A partnership between the brokerage XP Investimentos and the crypto asset manager Hashdex aims to allow investors easier access to funds that have…
  • 06/30/2020

What’s Summer Without Fear Of Bed Bugs? Many Are Likely To Find Out By Not Traveling

  • The New York Times writes about a silver lining for families who take staycations: no worries about visiting hotels and bringing home bed bugs. Public health news is on menopause, heat-related deat…
  • 06/30/2020

Impayés de loyers : collectivités et bailleurs débloquent des fonds

  • En Seine-Saint-Denis, notamment, de nombreux locataires sont en difficulté et sans aide particulière de l’Etat.
  • 06/30/2020

California Dairies Inc. closes Artesia plant

  • The 62-year-old manufacturing facility's closure will affect about 49 employees.
  • 06/30/2020

ASX stock of the day: Avita Therapeutics share price climbs 8.4% as company redomiciles

  • After redomiciling to the United States yesterday, the Avita Therapeutics Inc (ASX: AVH) share price is up 8.4% today.
  • 06/30/2020

Insurance Dept: Required Premium Relief Has Saved California Drivers $1.2B

  • California automobile insurance companies have agreed to provide $1.21 billion in savings to drivers, the state insurance department says. Insurance
  • 06/30/2020

Ouro, dólar e bolsa americana: conheça os investimentos mais rentáveis do primeiro semestre de 2020

  • Em meio à crise, investidores partem para investimentos considerados mais seguros; recomendação é pela diversificação do portfólio
  • 06/30/2020

Human Microbiome Therapeutics Market 2020-2024 | Growing Prevalence of Chronic Diseases to Boost Growth | Technavio

  • The Global Human Microbiome Therapeutics Market will grow by USD 276.93 mn during 2020-2024
  • 06/30/2020

España, en el furgón de cola de Europa por sus políticas de desarrollo

  • El Índice de Compromiso con el Desarrollo analiza el impacto de los países más allá de la ayuda
  • 06/29/2020

Opinion | Pourquoi le télétravail ne marchera pas en France

  • La généralisation du télétravail en France ne pourra se faire de façon durable, estime Samir Ayoub. Ce dispositif se heurtera à des difficultés trouvant leurs sources dans le droit, l’organisation sociale et l’héritage catholique de la France.
  • 06/29/2020

Les valeurs à suivre aujourd'hui à la Bourse de Paris Lundi 29 juin 2020

  • 06/29/2020

Les 4 grands chantiers (r)ouverts par le coronavirus

  • Et si les principaux changements liés au coronavirus ne s'étaient pas encore réellement fait sentir? Gestion des émotions au sein des entreprises, redéfinition de la relation de travail et du mode de management, question du sens, durée et types contrats: les chantiers ouverts sont énormes. Le BAO Group a tenté d'en baliser quelques-uns dans un livre blanc, fruit d'heures de discussions et de partage.
  • 06/29/2020

EN DIRECT DES MARCHES : Sanofi, L'Oréal, EDF, Air France, Worldline, Chesapeake, Boeing, Wirecard...

  • 06/29/2020

LCI: saiba como funciona a Letra de Crédito Imobiliário

  • A LCI (Letra de Crédito Imobiliário) é um tipo de investimento em renda fixa lastreado no mercado imobiliário. Saiba mais como funciona uma LCI.
  • 06/29/2020

LCA: saiba como funciona uma Letra de Crédito do Agronegócio

  • A LCA (Letra de Crédito do Agronegócio) é um título de crédito privado que direciona recursos para o setor do agronegócio. Saiba como a LCA funciona.
  • 06/29/2020

Rise and Shine: What you need to know before the ASX opens - Stockhead

  • On Stockhead today, the incredible discovery that shaped West Africa’s newest gold miner, the gold and nickel juniors cashed up and worth watching and renewables-focused stocks have been more resilient than the oil and gas guys. But first…   The week ahead The most important economic data this week includes trade data on Thursday and May’s …
  • 06/28/2020

Hot Money Monday: These are the most in-demand stocks on the ASX right now - Stockhead

  • Each Monday, Stockhead recaps which stocks are most heavily in demand by investors — running hot. The analysis is based on the Relative Strength Index (RSI), a technical gauge which measures how trading momentum is affecting the price action. A reading of 70 is seen as the level at which a company may have been …
  • 06/28/2020

BFM TV, RMC : le tour de passe passe de Patrick Drahi qui aidera à justifier le plan social

  • INFO CAPITAL. NextRadioTV, propriétaire de BFM TV et RMC, a lancé un plan social de près de 400 postes, bien que la société soit bénéficiaire. Toutefois, elle est en train d’absorber discrètement une
  • 06/28/2020

Ourinvest: sem segunda onda, FIIs retornam no fim do ano que vem

  • Segundo Rossano Nonino, diretor executivo da Ourinvest Real Estate, seguna onda de contágio, contudo, traz cenário incerto. Clique para ler.
  • 06/28/2020

Poucas coisas vão ter uma relação risco-retorno tão boa quanto ações americanas, diz Absolute

  • "As empresas que vão sair vencedoras (da crise) estão nos Estados Unidos", afirmou o gestor Fabiano Rios no episódio mais recente do podcast Outliers
  • 06/28/2020

Sanofi adapte ses structures à ses nouvelles ambitions

  • En supprimant un millier d'emplois dans l'Hexagone, le laboratoire français entérine son désinvestissement du cardiovasculaire et du diabète et son recentrage sur les vaccins. Bercy et les syndicats veulent que la France reste le navire amiral de l'entreprise.
  • 06/28/2020

Air France s'apprête à annoncer des milliers de suppressions de postes

  • Air France, durement frappée par la crise du Covid-19, se prépare à une semaine difficile sur le plan social, avec la présentation vendredi de l'impact sur l'emploi de son "plan de reconstruction" qui passera par une réduction drastique des liaisons intérieures et se traduira selon les syndicats par des milliers de postes supprimés, sans départs contraints. Avions cloués au sol, personnel en grande partie au chômage partiel
  • 06/28/2020

NEOVACS : PROJET DE REPRISE DE LA SOCIÉTÉ FAMAR LYON POUR RECRÉER UN ACTEUR MAJEUR DE L'INDUSTRIE DE LA SANTÉ ET DU MÉDICAMENT EN FRANCE

  • Paris et Boston, le 28 juin 2020 - 10h00 CET - NEOVACS (Euronext Growth Paris : ALNEV) annonce avoir présenté un projet de reprise de la société FAMAR LYON, en association avec les sociétés INDUSTRY et COFILUX, afin de recréer un acteur de référence de l'industrie pharmaceutique en France. Un acteur historique de l'industrie pharmaceutique en déficit d'investissements L'usine pharmaceutique FAMAR LYON de Saint-Genis Laval constitue l'un des berceaux de l'industrie pharmaceutique française
  • 06/28/2020

Sanofi veut supprimer un millier d'emplois en France, 1.700 en Europe

  • Tandis que le groupe français a multiplié les partenariats avec des acteurs privés américains ces derniers mois, notamment dans la course au vaccin contre le Covid-19, la CGT dénonce une "poursuite du démantèlement du groupe et de l'externalisation des activités". Sanofi emploie 25.000 personnes dans l'Hexagone.
  • 06/28/2020

Air France s'apprête à annoncer des milliers de suppressions de postes

  • Air France, durement frappée par la crise du Covid-19, se prépare à une semaine difficile sur le plan social, avec la présentation vendredi de l'impact sur l'emploi de son "plan de reconstruction" qui passera par une réduction drastique des liaisons intérieures et se...
  • 06/27/2020

Air France s'apprête à annoncer des milliers de suppressions de postes | Zone bourse

  • 06/27/2020

« Ils ne s’arrêtent jamais » : les syndicats de Sanofi s’indignent d’un énième plan social

  • Les dirigeants du géant pharmaceutique français doivent préciser, lundi 29 juin, le projet de suppression de près de 1 700 emplois en Europe, dont un millier en France.
  • 06/27/2020

Churchill Downs Incorporated : Reopens Presque Isle Downs & Casino in Erie, Pennsylvania | MarketScreener

  • 06/26/2020

"Il faut remettre l'humain au cœur du travail"

  • Et si les principaux changements liés au coronavirus ne s'étaient pas encore réellement fait sentir? Gestion des émotions au sein des entreprises, redéfinition de la relation de travail et du mode de management, question du sens, durée et types contrats: les chantiers ouverts sont énormes. Le BAO Group a tenté d'en baliser quelques-uns dans un livre blanc, fruit d'heures de discussions et de partage.
  • 06/26/2020

La grève se poursuit chez BFMTV

  • Les salariés ont voté une reprise de la grève jusqu'à lundi matin, mettant en péril la couverture des élections municipales. La direction estime avoir répondu aux principales revendications, mais les promesses sont insuffisantes selon les salariés.
  • 06/26/2020

Les valeurs à suivre lundi 29 juin 2020 à la Bourse de Paris

  • (AOF) - AWOX Convoqués en assemblée générale mixte, les actionnaires d'AwoX ont approuvé l'opération d'apport partiel d'actif par AwoX de sa branche d'activité retail de lighting connecté (hors accords
  • 06/26/2020

Les valeurs à suivre lundi 29 juin 2020 à la Bourse de Paris

  • 06/26/2020

Getlink : fin de cotation secondaire à Londres | Zone bourse

  • 06/26/2020

GETLINK : retiré de la cote à Londres | Zone bourse

  • 06/26/2020

Fermeture d'Euronext Londres : retrait de Getlink de la cote officielle de la bourse de Londres | Zone bourse

  • 06/26/2020

Fermeture d'Euronext Londres : retrait de Getlink de la cote | Zone bourse

  • 06/26/2020

Up and down the ladder: The latest comings and goings - STAT

  • From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry.
  • 06/26/2020

Xconomy: Bio Roundup: Gilead's Pionyr Grab, Relay to IPO, Unicorn Sana & More

  • Uncertainty related to the continued spread of the pandemic continued to consume most of the oxygen in the room this week, but life sciences news outside
  • 06/26/2020

Sanofi va supprimer 1.700 emplois en Europe, dont un millier en France

  • Une réorganisation qui correspond à une nouvelle stratégie et non à un plan social lié aux conséquences du Covid-19. Le groupe a d'ailleurs vu son chiffre d'affaires s'accroître pendant la crise et va augmenter son dividende.
  • 06/26/2020

Sanofi veut supprimer 1 700 emplois en Europe, dont un millier en France

  • Selon la direction, ce plan se fera « sur la base du volontariat » et doit s’étaler sur trois ans. Le laboratoire affichait un chiffre d’affaires en hausse au premier trimestre, avec près de 9 milliards d’euros.
  • 06/26/2020

Sanofi veut supprimer 1700 emplois en Europe, dont un millier en France

  • Le géant pharmaceutique français Sanofi a annoncé ce vendredi la suppression de 1 700 emplois en Europe, dont un millier en France, une réorganisation qui correspond à une « nouvelle stratégie » selo…
  • 06/26/2020

Sanofi veut supprimer 1700 emplois en Europe, la majorité en France | Zone bourse

  • 06/26/2020

«Pour relancer l’économie, nous devrons travailler davantage»

  • FIGAROVOX/TRIBUNE - L’économiste Claude Sicard estime que la relance de l’économie devra passer par une révision législative du droit du travail afin d’édicter de nouvelles normes, plus souples, en commençant par proclamer une loi d’urgence économique.
  • 06/26/2020

Sanofi va tailler dans l’emploi en France et en Europe

  • Sanofi veut supprimer 1.000 emplois en France et 700 dans le reste de l'Europe., Nouveau coup dur sur le front de l'emploi ! Le géant français de la santé Sanofi a annoncé vouloir supprimer 1.700 emplois
  • 06/26/2020

Sanofi veut supprimer 1700 emplois en Europe, dont 1000 en France

  • Ce plan sera basé «exclusivement sur la base du volontariat» et s'étalera sur trois ans. Sanofi emploie 25.000 personnes en France.
  • 06/26/2020

Weekly ASX Small Cap Wrap: Who's zapping books to kill COVID this week? - Stockhead

  • Some people will do anything to ensure they don’t get COVID — including apparently microwaving public library books. A library in Michigan in the US has told borrowers to stop microwaving books, noting that library books had security radio frequency identification tags that were made of metal. And we all know what happens when you microwave …
  • 06/26/2020

Crise du coronavirus : Usipanel s'en sort grâce aux vitres antipostillons

  • Chez Usipanel , le confinement n'a pas été synonyme de ralentissement. Au contraire, la cadence s'est même accélérée jusqu'à devoir...
  • 06/26/2020

La filière horticole saignée à blanc par le confinement

  • La filière horticole s'est trouvée privée de débouchés commerciaux dès le confinement alors que le printemps est une période cruciale pour l'horticulture. Le gouvernement a annoncé une enveloppe de 25 millions d'euros, mais cela ne couvre que la moitié des stocks que la filière a dû détruire.
  • 06/26/2020

Gabriel Leal, da XP, critica campanha do Itaú: "Desespero"

  • O sócio da XP Inc. falou também sobre o papel dos agentes autônomos de investimento, criticados pelo banco
  • 06/26/2020

L'emploi dans les banques installées en France a reculé en 2019, une érosion lente et continue

  • La Fédération bancaire française (FBF), fait le point sur l'emploi salarié dans les banques en France, et livre ses réflexions sur des sujets comme l'arrivée de l'intelligence artificielle ou l'exception française face aux vagues de licenciements constatés dans le monde.
  • 06/26/2020

Presse. Contre la grève, un petit chantage à l’emploi au Parisien

  • D’habitude, quand une entreprise se découvre de nouvelles ambitions, elle embauche en conséquence. Au Parisien, c’est l’inverse...
  • 06/25/2020

Western Digital : New NVMeS SSDs and NVMe-oFS Solutions | MarketScreener

  • 06/25/2020

Les salariés de BFM-TV et de RMC votent la reprise de la grève jusqu’à lundi matin

  • NextRadioTV, filiale du groupe Altice, prévoit de supprimer jusqu’à 380 CDI en raison d’un écroulement des recettes publicitaires.
  • 06/25/2020

BFM/RMC : les salariés votent la reprise de la grève jusqu'à lundi matin

  • Les salariés des chaînes de télé et radio de NextradioTV ont provoqué jeudi soir une interruption du direct pendant une heure mais le débat entre les candidates des élections municipales à Paris a été maintenu.
  • 06/25/2020

Daher : 1.300 en postes menacés dans l'Hexagone

  • Le minimum sera entre 500 et 600 postes. Le groupe espère sauver des postes grâce au soutien de l'Etat. , L'équipement aéronautique Daher subit à son tour le contrecoup de la crise économique causée par
  • 06/25/2020

L'équipementier aéronautique Daher s'apprête à réduire la voilure

  • L'onde de choc de la crise du coronavirus commence à se faire sentir dans le secteur aéronautique: l'équipementier Daher a annoncé jeudi qu'il prévoyait de supprimer jusqu'à 1.300 postes de CDI dans le cadre d'un plan de restructuration
  • 06/25/2020

L'équipementier aéronautique Daher va supprimer jusqu'à 1300 postes de CDI - RFI

  • L'avionneur et équipementier aéronautique Daher, dont l'activité a été fortement affectée par la crise due au coronavirus, prévoit de supprimer jusqu'à 1300 postes en CDI dans le cadre d'un plan de r…
  • 06/25/2020

Dinheiro para reserva de emergência? Especialistas listam opções mais rentáveis que a poupança

  • Tesouro Selic, fundos DI e CDBs são alternativas mais vantajosas para a criação de um colchão de liquidez pelo investidor
  • 06/25/2020

"O SUNO30 será mais moderno do IFIX", diz prof. Baroni

  • Para o vice-presidente de pesquisa de FIIs da Suno, Marcos Baroni, o SUNO30 será melhor do que outros indicadores. Clique aqui e saiba mais.
  • 06/25/2020

BorgWarner Automotive va fermer son site corrézien, plus de 350 emplois menacés

  • 06/25/2020

3 Biotech Stocks Under $5 With 100%-Plus Upside Potential

  • Biotech stocks give a whole new meaning to risk/reward plays. Unlike names inhabiting other areas of the market, these tickers can witness explosive movements in the blink of an eye, giving them a Street reputation for their high volatility.Companies in the biotech industry are unique in that their long-term growth prospects don’t necessarily hinge on quarterly profit results. Rather, clinical trial data or verdicts from regulatory bodies can have a more meaningful impact as product approvals indicate vital revenues are on the horizon. This means any positive development can act as a catalyst that sends shares skyrocketing. The flip-side, however, does hold true, so the risk-averse tend to shy away from these names.So, how are investors supposed to determine which biotech stocks are capable of outperforming the rest? Tracking the analyst community’s activity can be an effective strategy. The pros, who have in-depth knowledge of the industry, offer insight into many biotechs, some of which fly relatively under-the-radar.Bearing this in mind, we used TipRanks’ database to track down affordable yet compelling biotech plays. After combing through the densely packed sector, we found three going for less than $5 apiece with bullish reviews from Wall Street analysts and over 100% upside potential. Spectrum Pharmaceuticals (SPPI)Primarily targeting diseases in hematology and oncology, Spectrum Pharmaceuticals hopes its therapies will be able to address the unmet medical needs of patients. With a $3.08 share price, some analysts believe that now is the ideal time to snap up shares.Writing for H.C. Wainwright, 5-star analyst Edward White remains focused on its novel long-acting granulocyte colony stimulating factor (GCSF) designed to stimulate neutrophil production for the treatment of chemotherapy induced neutropenia patients, Rolontis. Ahead of the candidate’s October 24 PDUFA date, the analyst highlights that Rolontis isn’t a biosimilar, and calls for 2020 sales of $3 million. Underscoring the huge potential here, he estimates sales will reach $300 million in 2026.“Pricing in the market seems to be rational with the competition appearing more typical of a branded drug market rather than a generic drug market. Management noted that about 1 million units of GCSF are dispensed per year and that ASP price has been compressing between branded drugs and biosimilars. Despite the COVID-19 pandemic, the company has plenty of inventory available to support the commercial launch of Rolontis,” White commented.It should also be noted that given the uncertainty surrounding COVID-19, management is planning for both a traditional and a virtual launch. In addition, SPPI is set to have a sufficient sales force on board in time for the commercial launch.Looking at the clinical trial for Rolontis dosed on the same day as chemotherapy, White argues that the design should bode well for SPPI. “As this is an open-label study, the company can see early data before deciding to continue with development. Though data for a label change are years away, if the data are positive, this study could help dramatically change Rolontis’ market share in the future as we believe same day dosing in a post-COVID-19 world could be a game changer,” he explained.With ZENITH20 Cohort 1 Poziotinib data at AACR demonstrating “there may be some hope yet”, the deal is sealed for White. In addition to reiterating a Buy recommendation, he left his price target at $11. This target implies shares could climb 250% higher in the next year. (To watch White’s track record, click here) Overall, though not many have weighed in with an opinion on SPPI in the last 3 months, those who have are singing its praises loudly. Overall, two analysts rate the stock a Buy, and the $9.50 average price target puts the potential twelve-month gain at 202%. (See SPPI stock analysis on TipRanks)Seres Therapeutics (MCRB)Taking its place at the forefront of microbiome therapeutics, Seres Therapeutics wants to transform the treatment of a wide range of diseases by modulating the function of the human microbiome. Based on the multiple catalysts slated for 2020 as well as its $4.73 share price, it’s no wonder MCRB is getting glowing reviews from several members of the Street.Standing squarely in the bull camp is 5-star analyst Gbola Amusa, of Chardan Capital. He points out that enrollment for the Phase 3 ECOSPOR III trial evaluating SER-109's ability to prevent recurrent C. difficile infection (rCDI) is complete, with the candidate already receiving Breakthrough Therapy Designation.As for the implications of this development, Amusa noted, “With positive results on the expected mid-2022 readout, ECOSPOR III has the potential to be a single pivotal study for the FDA; Seres plans to initiate a SER-109 Expanded Access Program.”Adding to the good news, the company has taken strides forward when it comes to the advancement of the clinical development for its rationally-designed, fermented microbiome medicine, SER-155, for the prevention of mortality due to gastrointestinal infections, bacteremia and graft versus host disease (GvHD) in immunocompromised patients.It should be noted that management told investors COVID-19 could impact its SER-287 Phase 2b and SER-401 Phase 1b clinical readouts. This is because the pandemic has put non-essential procedures including endoscopies on hold, and thus, it has been challenging to reach enrollment targets on time. That being said, the company doesn’t believe the availability of its product candidates for ongoing studies will experience any disruptions.While a potential data readout delay has alarmed some investors, Amusa remains unphased. “Even with Covid-19-related uncertainties on SER-287 and SER-401, we continue to see 2020 as a catalyst rich year for Seres on the ECOSPOR III results alone, which with positive results could lead to SER-109 becoming the first FDA-approved microbiome medicine. Even with recent movements, the current MCRB market cap of $334 million to us is still modest in relation to the risk-adjusted opportunities represented by the pipeline,” he explained.In line with his optimistic take, Amusa rates MCRB a Buy along with a $12.50 price target. This leaves room for shares to soar 151% in the next year. (To watch Amusa’s track record, click here) Do other analysts agree with Amusa? They do. Only Buy ratings, 4, in fact, have been issued in the last three months, so the consensus rating is a Strong Buy. At $9.63, the average price target puts the potential twelve-month gain at 91%. (See MCRB stock analysis on TipRanks)Akari Therapeutics (AKTX)Last up to bat we have Akari Therapeutics, which develops innovative treatments for autoinflammatory diseases involving the complement (C5) and leukotriene (LTB4) pathways. Given its strong execution and share price of only $2.14, is now the right time to get in on the action?According to B.Riley FBR’s Mayank Mamtani, the answer is a resounding yes. At the end of May, the company provided an update on the progress of the clinical trials for bullous pemphigoid (BP), atopic keratoconjunctivitis (AKC) and pediatric transplant-induced thrombotic microangiopathy (HSCT-TMA) indications for its lead program, nomacopan. The candidate is also getting attention for its potential as a therapeutic option for COVID-19 patients.The 5-star analyst thinks the full Phase 2 BP study results, as well as an orphan designation granted by the FDA and EMA, free AKTX up to kick off end-of-Phase 2 meetings with the FDA and EMA in Q3 2020 to discuss the pivotal Phase 3 trial design. These meetings would address important considerations including enrolling severe patients in addition to mild and moderate, increasing treatment duration from 1.5 to 6 months, an option to dose at 30 mg-plus levels and a choice of active versus comparator arms, including possibly combining or sequencing with steroids.“There were no treatment-related serious AEs, in line with the favorable tolerability profile noted in other indications (e.g., PNH), highlighting further differentiation relative to steroid standard of care,” Mamtani stated.However, Mamtani doesn’t dispute the fact that the COVID-19 pandemic has delayed site initiation activities for the Phase 3 HSCT-TMA trial to later in 2020 and the enrollment for the Part B placebo-controlled efficacy cohort of the Phase 1/2 study in severe AKC patients has been halted. That said, Mamtani notes “the interim update remains on track for mid-2020 in ~2/3rd of the targeted 16 patients already enrolled in the study.” He added, “The prior open-label data of nomacopan eye drops demonstrated in three severe atopic keratoconjunctivitis (AKC) patients rapid overall improvement in composite clinical scores of symptoms and signs.”On top of this, preclinical data has found complement (C5) and leukotriene (LTB-4) pathways may play a role in severe lung inflammation and microthrombi and organ damage associated with COVID-19. This creates an opportunity for nomacopan as it has been shown to produce a “profound and broad-acting anti-inflammatory effect.”To wrap it all up, Mamtani commented, “We believe AKTX has held up well in the volatile macro environment as investors look to take advantage of the depressed stock levels for this late-stage biotech supported by robust clinical data generated in earlier-stage trials, with incremental Phase 1/2 severe AKC placebo-controlled data anticipated in mid-2020.”Everything the company has going for it prompted Mamtani to stay with the bulls. Along with a Buy rating, he kept his $5 price target as is, bringing the upside potential to 134%. (To watch Mamtani’s track record, click here) Turning now to the rest of the Street, it has been quiet when it comes to other analyst activity. Mamtani’s call was the only one issued recently.
  • 06/25/2020

En baisse de 1%, l'emploi dans le secteur bancaire poursuit sa lente érosion en France

  • (Reuters) - L'emploi dans le secteur bancaire en France s'est contracté de 1,0% en 2019, continuant sa lente érosion, selon les chiffres publiés jeudi par la Fédération bancaire française (FBF). Le secteur qui employait 360
  • 06/25/2020

En baisse de 1%, l'emploi dans le secteur bancaire poursuit sa lente érosion en France | Zone bourse

  • 06/25/2020

RPT-En baisse de 1%, l'emploi dans le secteur bancaire poursuit sa lente érosion en France

  • (Répétition titre avec en France) 25 juin (Reuters) - L'emploi dans le secteur bancaire en France s'est contracté de 1,0% en 2019, continuant sa lente érosion, selon les chiffres publiés jeudi par la Fédération bancaire française (FBF). Le secteur qui employait 360
  • 06/25/2020

Des emplois pérennes et qualifiés dans le secteur bancaire

  • 06/25/2020

Le chômage baisse en France, mais se maintient à un niveau élevé

  • En mai, le nombre de demandeurs d’emploi sans aucune activité a décliné de 149 900. Il reste important, avec 4,42 millions de personnes dans cette situation.
  • 06/25/2020

Top Analysts See 100%-Plus Upside Potential in These 3 Penny Stocks

  • Penny stocks give a whole new meaning to risk/reward plays. These tickers can witness explosive movements in the blink of an eye, giving them a Street
  • 06/25/2020

Les antennes de BFMTV perturbées par une grève contre des suppressions de postes

  • Les antennes de BFMTV, RMC et RMC Découverte étaient perturbées mercredi matin par la première grève de son histoire, contre les suppressions de postes prévues par la filiale d'Altice.
  • 06/25/2020

Médias. Écrans noirs et micros silencieux à BFM TV et RMC

  • Les salariés du groupe NextRadioTV, filiale d’Altice, ont entamé un mouvement de grève historique contre un plan social de grande ampleur, payant les pots cassés d’une stratégie aventureuse.
  • 06/24/2020

Emploi: l'Elysée fixe les taux du chômage partiel classique et longue durée

  • Trois semaines après le lancement d'une concertation pour "sauver l'emploi", Emmanuel Macron a reçu à nouveau mercredi les leaders syndicaux et patronaux pour leur dévoiler de premiers arbitrages sur le nouveau dispositif de chômage partiel de longue durée et le chômage partiel classique, qui ont été accueillis avec quelques réserves des partenaires sociaux. Alors que l'Unédic anticipe la destruction de 900
  • 06/24/2020

Le marché du travail se réveille avec le déconfinement

  • Le nombre d'embauches a fortement grimpé en mai, notamment celles en contrats courts. Dans l'hôtellerie-restauration et la santé, le nombre d'offres d'emploi est deux fois plus important qu'avant le confinement. Mais les craintes d'une hausse du chômage dans les prochains mois demeurent, surtout pour les jeunes.
  • 06/24/2020

Aider les jeunes à passer le cap de la crise

  • 06/24/2020

Les sénateurs avancent leurs solutions pour la relance économique

  • Décentralisation des décisions, baisse de la TVA dans certains secteurs... Les élus ont fait entendre des divergences avec les intuitions de l’exécutif.
  • 06/24/2020

BFM-TV : suspension de la grève, le débat du 2e tour des municipales à Paris reporté

  • Après avoir renoncé au débat qui devait l’opposer à ses adversaires Agnès Buzyn et Rachida Dati sur BFM-TV, dont les salariés sont en grève mercredi, Anne Hidalgo avait demandé son report.
  • 06/24/2020

La crise va accélérer l’essor du Management de transition

  • Les entreprises ayant besoin de se réorganiser rapidement pourraient faire appel à ces profils d’experts.
  • 06/24/2020

Le projet de loi sur la recherche «pas à la hauteur», selon le Cese

  • 06/24/2020

Recherche: le projet de loi "pas à la hauteur", selon le Cese

  • Le Conseil économique, social et environnemental (Cese), saisi par le gouvernement sur le projet de loi pluriannuel de la recherche, a rendu mercredi un avis très critique à l'encontre d'un texte qui n'est selon lui "pas à la hauteur" pour redonner du souffle au système. Le projet de loi LPPR, qui doit être présenté le 8 juillet en Conseil des ministres, prévoit un investissement de 25 milliards d'euros sur dix ans pour donner de la visibilité et des moyens à la recherche, fragilisée par un sous-investissement chronique
  • 06/24/2020

La grève chez BFM et RMC très suivie, le débat pour les municipales reporté

  • Les salariés protestent contre le plan de la direction qui vise près d’un tiers des 1600 salariés. Ils craignent des départs contraints.
  • 06/24/2020

Western Digital's New NVMe™ SSDs and NVMe-oF™ Solutions Provide the Foundation for Next-Generation, Agile Data Infrastructures | | IT Business Net

  • Strengthening its Data Center Portfolio, Company's New Dual-Port, Performance Ultrastar® DC SN840 NVMe SSD, OpenFlex™ Data24 NVMe-oF Platform and RapidFlex™ Controllers Extend the Value of NVMe t
  • 06/24/2020

Grève inédite à BFM contre des suppressions de postes massives - France 24

  • Grève inédite à BFM contre des suppressions de postes massives
  • 06/24/2020

Les antennes de BFMTV perturbées par une grève contre des suppressions de postes

  • Les antennes de BFMTV, RMC et RMC Découverte étaient perturbées mercredi matin par la première grève de son histoire, contre les suppressions de postes prévues par la filiale d'Altice. "C'est une Première édition fabriquée dans des conditions particulières après l'annonce d'un plan de restructuration qui prévoit des suppressions de postes", a indiqué à plusieurs reprises un des présentateurs de la matinale de BFMTV, Christophe Delay
  • 06/24/2020

Rebond des embauches de 75% en mai, selon l'Acoss

  • Le nombre de déclarations d'embauche de plus d'un mois (hors intérim) a rebondi de 75,9% en mai avec le déconfinement mais reste en recul de 52,7% sur trois mois, a indiqué jeudi l'Agence centrale des organismes de sécurité sociale (Acoss). Ce rebond intervient après une chute de 64,2% en avril et 24,9% en mars
  • 06/24/2020

Les antennes de BFMTV perturbées par une grève contre des suppressions de postes

  • La filiale de médias du groupe Altice a dévoilé le 17 juin un vaste plan d'économies et "de reconquête" pour faire face à l'impact de la crise du Covid-19 et à une concurrence accrue. , Les
  • 06/24/2020

Rebond des embauches de 75% en mai, selon l'Acoss

  • 06/24/2020

Les antennes de BFMTV perturbées par une grève contre des suppressions de postes - France 24

  • Les antennes de BFMTV perturbées par une grève contre des suppressions de postes
  • 06/24/2020

Citigroup Inc. Raises Stock Position in Seres Therapeutics Inc (NASDAQ:MCRB)

  • Citigroup Inc. grew its holdings in Seres Therapeutics Inc (NASDAQ:MCRB) by 15.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 15,802 shares of the biotechnology company’s stock after acquiring an additional 2,060 shares during the period. Citigroup Inc.’s holdings in Seres […]
  • 06/24/2020

Emploi: les partenaires sociaux à l'Elysée, des annonces sur le chômage partiel attendues

  • Trois semaines après le lancement d'une concertation pour "sauver l'emploi", Emmanuel Macron reçoit à nouveau mercredi les partenaires sociaux pour leur dévoiler de premiers arbitrages, notamment sur le nouveau dispositif de chômage partiel de longue durée. Alors que l'Unédic anticipe la destruction de 900
  • 06/24/2020

Western Digital’s New NVMe™ SSDs and NVMe-oF™ Solutions Provide the Foundation for Next-Generation, Agile Data Infrastructures

  • Western Digital (NASDAQ: WDC) today announced new solutions that provide the foundation for next-generation data infrastructures designed around Ultra
  • 06/24/2020

Synex International Inc. Signs Letter of Intent to Acquire All of the Wind Projects of Sea Breeze Power Corp. and Divests of Its Interest in Robson Valley Power Corporation | MarketScreener

  • 06/23/2020

Conselho do FGTS formaliza veto de Bolsonaro, que reduz rendimento do fundo

  • O FGTS volta a repassar distribuir parte do lucro aos cotistas, mas o percentual exato será definido apenas na próxima reunião do Conselho
  • 06/23/2020

Suppressions de postes à BFMTV et RMC : appel à la grève mercredi

  • Les salariés des médias de NextRadioTV, détenu par Altice, ont approuvé mardi en assemblée générale un appel pour une grève de 24 heures le 24 juin. Ils s'opposent au plan de restructuration présenté par la direction, qui prévoit le licenciement de près d'un tiers des effectifs.
  • 06/23/2020

Appel à la grève à BFM-TV/RMC contre un projet de suppression de plusieurs centaines d’emplois

  • La filiale du groupe Altice, propriété de Patrick Drahi, avait dévoilé, le 17 juin, un vaste plan d’économies pour, selon la direction, faire face à l’impact de la crise du Covid-19.
  • 06/23/2020

Fonds de solidarité : de nouveaux changements

  • Mis en place par les pouvoirs publics au tout début de l’épidémie de Covid-19 , le fonds de solidarité permet aux petites entreprises...
  • 06/23/2020

Orchestra-Prémaman : les choses se compliquent pour la reprise de l'enseigne

  • Business Insider est le site d’actualité économique qui connait la plus forte croissance au monde.
  • 06/23/2020

Suppressions de postes chez BFMTV et RMC : un appel à la grève de 24 heures mercredi

  • Le groupe a annoncé la semaine dernière un vaste plan de restructuration, qui supprimerait près d'un poste sur trois.
  • 06/23/2020

Post Covid-19 : un ralentissement brutal du march

  • Directeurs des syst
  • 06/23/2020

Coronavirus en France: les professionnels du tourisme, grands oubliés de la crise

  • En France, les professionnels du tourisme et de l’événementiel et de la culture, dont les activités se sont arrêtées brutalement à cause du coronavirus, se sont mobilisés ce lundi 22 juin dans plusie…
  • 06/22/2020

BFMTV/RMC: les rédactions s'inquiètent pour «le maintien de la qualité éditoriale»

  • 06/22/2020

Faillites, suppressions d'emplois: les effets collatéraux du virus - France 24

  • Faillites, suppressions d'emplois: les effets collatéraux du virus
  • 06/22/2020

Faillites, suppressions d'emplois: les effets collatéraux du virus

  • La crise du coronavirus a précipité plusieurs entreprises françaises, dont certaines étaient déjà en difficultés, dans des faillites ou restructurations lourdes de conséquences pour l'emploi. - Automobile - - Renault, en difficulté financière, prévoit la suppression d'environ 15
  • 06/22/2020

Seres Therapeutics : Appoints Terri Young, Ph.D., R.Ph., Experienced Commercial Leader, as Executive Vice President, Chief Commercial and Strategy Officer | MarketScreener

  • 06/22/2020

Seres Therapeutics Appoints Terri Young, Ph.D., R.Ph., Experienced Commercial Leader, as Executive Vice President, Chief Commercial and Strategy Officer

  • Seres Therapeutics announces the appointment of Terri Young, Ph.D., R.Ph., as Executive Vice President, Chief Commercial and Strategy Officer.
  • 06/22/2020

Automobile : menace sur le site de Getrag Ford

  • Les syndicats du site qui emploie 800 personnes à Blanquefort, près de Bordeaux, ont déclenché la première phase d’un droit d’alerte.
  • 06/22/2020

Seres Therapeutics (MCRB) Reports Q2 Loss, Tops Revenue Estimates

  • Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 42.86% and 21.78%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
  • 08/06/2019

Seres Therapeutics (MCRB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

  • Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  • 07/25/2019

Largest insider trades of the week: June 21

  • The GuruFocus All-in-One Screener can be used to find insider trades from the past week.
  • 06/21/2019

Seres Therapeutics (MCRB) CEO Eric Shaff on Q1 2019 Results - Earnings Call Transcript

  • Seres Therapeutics (MCRB) CEO Eric Shaff on Q1 2019 Results - Earnings Call Transcript
  • 05/06/2019

5 New Stocks Trading Under $10 With Monumental Implied Upside

  • Most firms on Wall Street focus on large and mega cap stocks, as they provide a degree of safety and liquidity.
  • 05/04/2019

Seres Therapeutics (MCRB) Reports Q1 Loss, Lags Revenue Estimates

  • Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -27.91% and -15.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
  • 05/02/2019

Here's Why Seres Therapeutics Stock Soared Today

  • A new collaboration with AstraZeneca could give microbiome-based medicine a big lift.
  • 03/11/2019

5 Stocks Trading Under $10 That Could Have Gigantic Upside Potential

  • While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
  • 03/08/2019
Unlock
MCRB Ratings Summary
MCRB Quant Ranking